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ABSTRACT

Endogenous cannabinoids (endocannabinoids) exert a wide range of
biological effects. In addition to having their well-known neurobehavioral effects,
a role for the major endocannabinoid anandamide (N-arachidonoyl ethanolamide;
AEA), in the cardiovascular system in various pathological conditions has been
reported. The aim of this thesis is to explore the effects of AEA on contractility,
Ca2+ signaling, and action potential (AP) characteristics in rat ventricular
myocytes. A video edge detection system was used to measure myocyte
shortening. Intracellular Ca2+ was measured in cells loaded with the fluorescent
indicator fura-2 AM. AEA (1 μM) caused a significant decrease in the amplitude
of electrically-evoked myocyte shortening. The effect of AEA was not altered in
the presence of pertussis toxin (PTX), AM251 and SR141716 (CB1 antagonists) or
AM630 and SR 144528 (CB2 antagonists). AEA also caused a significant decrease
in the amplitudes of electrically-evoked Ca2+ transients. However, the amplitudes
of caffeine-evoked Ca2+ transients and the rate of recovery of electrically-evoked
Ca2+ transients following caffeine application were not altered. In the whole-cell
mode of patch-clamp technique, AEA (1 μM) significantly decreased the duration
of APs. The inhibition was not altered in the presence of PTX, AM251 and
AM630. Furthermore, AEA inhibited voltage-activated inward Na+ (INa) and Ca2+
(IL,Ca) currents; major ionic currents shaping the APs in ventricular myocytes, in a
voltage and PTX-independent manner. Cardiac Na+/Ca2+ exchanger (NCX1)mediated currents were also suppressed by AEA. The effect of AEA was not
influenced by the inhibition of fatty acid amide hydrolase (FAAH) or in the
presence of PTX, AM251 and AM630 or following the inclusion of GDP-β-S in
pipette solution. The results of this study indicate for the first time that impaired
VI

Ca2+ signaling underlies the negative inotropic actions of AEA in rat ventricular
myocytes, and that the direct interaction of AEA with ion channel(s) shaping APs,
mediates, at least in part, the effects of AEA on myocyte contractility. In addition,
the results indicate for the first time that, under normal conditions, AEA can
directly inhibit the activity of NCX1 in ventricular myocytes. In view of the
massive release of various N-acylethanolamines (NAEs), including AEA, during
cardiac ischemia and hypoxic conditions, further understanding of their
mechanism(s) of action and target proteins is essential in the development of
better treatment modalities under pathological conditions.
Keywords: Endocannabinoids, anandamide, myocyte shortening,
activated inward Na+ current, voltage-activated inward Ca2+ current.
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1. INTRODUCTION
1.1. Cardiac cell electrophysiology
1.1.1 Cardiac action potential
Physiological function of the heart results from the periodic execution of a
series of coordinated and interdependent mechanical, chemical, and electrical
processes within the cardiac tissue. An important event central to these processes
is the cardiac action potential (AP) and the mechanism by which this electrical
excitation initiates cardiac muscle contraction is called excitation-contraction
coupling.
The AP of a cardiac cell arises from the coordinated opening and closing
(gating) of ion channels; membrane proteins that control ion passage across cell
membranes and constitute the molecular foundation for the generation of APs.
Depending on the cell type, the transmembrane voltage in resting cardiac tissue
cells ranges from -60 mV to -90 mV, where the intracellular space is negatively
charged with respect to the extracellular space due to the differences in ion
concentration that exist between the intracellular and the extracellular milieu
(Grant, 2009). This concentration difference not only gives rise to diffusion of
ions across the membrane, but also generates a potential difference that
counteracts the diffusion and determines the electrochemical equilibrium
according to the Nernst Equation (Kettenmann, et al., 1983). It is also important to
note that due to involvement of multiple ions, the sum of conductances of
different ion channels determines the final value of the resting membrane
potential.
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The electrophysiological characteristics of excitable cells are shaped in
large part by the regulation of voltage-gated ion channels (VGICs). These
channels are deemed voltage-gated since changes in membrane potential lead to
alterations in their conformation or gating characteristics. Voltage-gated ion
channels comprise three main families: Na+, Ca2+ and K+ channels (Bezanilla,
2005). In general, at any given moment, VGICs can be found in one of three
gating states; closed, open, or inactive (Karmazinova and Lacinova, 2010).
Channels in their closed state can be opened by an appropriate change in
membrane potential. Channels in their open state allow the generation of ionic
conductance for a particular permeable ion. However, in the inactive state,
channels at depolarized potentials enter a transient non-conducting refractory
period in which no changes in membrane potential can re-open them. After this
refractory period, inactive channels can return to their closed state and become
available for the generation of the next AP (Bahring and Covarrubias, 2011).
The AP in a ventricular muscle cell lasts for 200-300 ms and is divided
into five sequential phases: resting (phase 4), upstroke (phase 0), early
repolarization (phase 1), plateau (phase 2), and final repolarization (phase 3)
(figure 1.1) (Amin, et al., 2010). At the resting membrane potential, Na+ and Ca2+
channels are mainly in the closed state and the activity of K+ channels, especially
the inwardly rectifying K+ (KIR) channels, determine the resting membrane
potential. Because the resting state has higher permeability to K+, resting
membrane potential of most ventricular cardiomyocytes stabilizes near the voltage
required to oppose the K+ concentration gradient, i.e., the K+ equilibrium potential
(Chung and Kuyucak, 2002). Upon the arrival of a brief, suprathreshold
depolarizing stimulus, voltage-gated Na+ channels (VGSCs) in the resting state
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Figure 1.1 Cardiac action potential and cardiac ion currents: The cardiac
action potential is generated by transmembrane inwardly and outwardly directed
ion currents. The inward (depolarizing) Na+ and Ca2+ currents point downwards.
The outward (repolarizing) K+ currents are pointed upwards. Adapted from Amin,
et al., 2010.
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begin to open allowing for the rapid influx of Na+ ions into the cell down their
electrochemical gradient. The influx of positively charged Na+ ions further
depolarizes the membrane resulting in the opening of more Na+ channels and
progressively increasing Na+ influx (phase 0). This fast feed forward mechanism
will bring the membrane potential towards Na+ equilibrium value which is about
20 mV. It is important to note that this initial depolarizing phase is central to fast
impulse propagation within the cardiac muscle. During depolarization, Na+
channels rapidly enter their inactive state in which no amount of stimulus will reopen them and Na+ current decays within a few milliseconds (Grant, 2009;
Moreno, et al., 2012). Following this initial upstroke, a first repolarization phase,
coined phase 1, is initiated by the opening of a particular K+ channel that
generates a transient outward current (Ito) and causes a repolarizing notch in the
AP (Dong, et al., 2006). Meanwhile, the Ca2+ channels, which exhibit slower
kinetics than Na+ channels, also open in response to depolarization leading to a
period of prolonged (100-200 ms) depolarization of the membrane potential called
the plateau phase of the AP (phase 2). This plateau phase results from a delicate
balance between depolarizing (inward) and repolarizing (outward) currents (Qu
and Chung, 2012). During the prolonged depolarization, VGCCs begin to
inactivate, while delayed rectifier K+ channels begin to activate. Eventually, the
prevailing repolarizing current carried by K+ channels brings the membrane back
towards the resting membrane potential (phase 3) (Moreno, et al., 2012; Grant,
2009). As mentioned earlier, the resting state of the AP (phase 4) is maintained by
the KIR. This channel is the primary conductance controlling the resting potential,
and permitting a significant repolarizing current during the terminal stage of the
AP (Wu, et al., 2012).
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The characteristic shape of the AP changes significantly across the
myocardial wall from the endocardium, midmyocardium, to epicardium. For
example, epicardial cells have a prominent phase 1 and a shorter duration of AP
(Voitychuk, et al., 2012). On the other hand, AP duration is the longest in the
midmyocardial region of ventricular muscle (Antzelevitch, et al., 1991; Grant,
2009).
1.1.2 Cardiac inward ion currents
1.1.2.1 Voltage-gated Na+ channels
Voltage-gated Na+ channels (VGSCs) play an essential role in the initiation
and propagation of APs in neurons and other excitable cells such as cardiac
myocytes (Catterall, et al., 2005a). The voltage-gated Na+ channel is a large
multimeric complex, consisting of an α subunit associated with auxiliary β
subunits (Figure 1.2) (Catterall, 2012). The pore forming α subunit is large
(molecular weight is about 227 kDa) and is sufficient for functional expression,
but the kinetics and the voltage dependence of channel gating are modified
significantly in the presence of the β subunits. In the heart, the Na+ channels
contain β1 through β4 subunits. These auxiliary subunits are involved in channel
localization and interaction with cell adhesion molecules, extracellular matrix and
intracellular cytoskeleton (Catterall, et al., 2005a).
Analysis of the primary sequence predicts that the α subunit folds into four
main domains (I-IV), that are similar to one another and contain six
transmembrane α helices (S1-S6). In each of the domains, the voltage sensor is
located in the S4 segments which contain positively charged amino acid residues
at every third position. These residues move across the membrane to initiate
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Figure 1.2 Structure of voltage-gated Na+ channel: The α subunit of Na+
channel is illustrated together with the β1 and β2 subunits. Roman numerals
indicate the α subunit domains; segments 5 and 6 are the pore-lining segments and
the S4 helices make up the voltage sensors. Modified from Catterall, 2012.
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channel activation in response to membrane depolarization. The short intracellular
loop connecting the homologous domains III and IV serves as the inactivation
gate, folding into the channel structure and blocking the pore from the inside
during sustained depolarization of the membrane. A re-entrant loop between
helices S5 and S6 is embedded into the transmembrane region of the channel in
order to form the narrow ion-selective filter at the extracellular end of the pore.
The wider intracellular end of the pore is formed by the four S6 segments. Small
extracellular loops connect the transmembrane segments, with the largest ones
connecting the S5 or S6 segments to the membrane re-entrant loop (Yu and
Catterall, 2003; Catterall, et al., 2005a).
According to the primary sequence of the α subunit, nine subtypes of Na+
channels (Nav1.1-Nav1.9) have been functionally characterized (Dib-Hajj, et al.,
2009; Yu and Catterall, 2003; Catterall, et al., 2005a). The nine Na+ channel
isoforms are greater than 50% identical in amino acid sequence in the
transmembrane and extracellular domains (Catterall, et al., 2005a). Generally,
Nav1.1 and Nav1.3 are localized in the soma of the neuron, while Nav1.2 subtype
is expressed mainly in unmyelinated axons. Moreover, Nav1.1 and Nav1.6
subtypes are highly expressed in peripheral nervous system, and Nav1.4 and
Nav1.5 subtypes are found in skeletal and cardiac myocytes, respectively (Rogart,
et al., 1989). Cardiac Na+ channels (Nav1.5) have a conductance of 19-22 pS
(Catterall, et al., 2005a). The fraction of channels available for opening varies
from about 100 % at -90 mV to zero at around -40 mV (Yu and Catterall, 2003;
Grant, 2009).
The cardiac Nav1.5 channel has consensus sites for phosphorylation by
protein kinase A (PKA), protein kinase C (PKC) and Ca2+-calmodulin kinase
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(Catterall, et al., 2005a). Moreover, biochemical studies have shown that purified
Na+ channels are phosphorylated by the cAMP-dependent PKA and PKC at
multiple sites in the intracellular loop between domains I and II (Cantrell and
Catterall, 2001). Although, in earlier studies, Na+ currents have been shown to be
modulated by the cAMP pathway, the results of these experiments are not
conclusive; some studies reporting a decrease, whereas others reporting an
increase in the Na+ current (Ono, et al., 1989; Kirstein, et al., 1996; Frohnwieser,
et al., 1997). However, functional studies have consistently found that
phosphorylation of the channel by PKC results in a decrease in INa (Murray, et al.,
1997; Hallaq, et al., 2012). In a recent study, it was reported that a mutation in
glycerol-3 phosphate dehydrogenase like 1 kinase was associated with Brugada
syndrome, and resulted in differential modulation of Na+ channel activity. In this
study, in vitro expression of the channel showed that mutated enzyme action is
associated with a decrease in INa (London, et al., 2007).
Modulation of Na+ channel currents is undoubtedly important in vivo,
although specific deficits that directly affect the function of Na+ channel are not
yet known. In the heart, point mutations and deletions in Nav1.5 cause long QT
syndrome and idiopathic ventricular fibrillation due to a slow and an incomplete
inactivation of the cardiac Na+ current resulting in prolongation of the AP
(Keating and Sanguinetti, 2001). It has also been shown that mutations that subtly
alter Na+ channel function, can lead to human diseases of hyperexcitability (Yu
and Catterall, 2003).
Besides genetic modification, various pharmacological agents also modify
the function of Na+ channels. For example, Na+ channels are activated by a
number of compounds such as veratridine, batrachotoxin and aconitine, and
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blocked by tetrodotoxin (TTX), saxitoxin, local anesthetics and antiarrhythmic
drugs (Yu and Catterall, 2003). In this context, it is important to note that although
neuronal Na+ channels have high sensitivity to TTX (in nanomolar concentration),
cardiac Na+ channels are only affected at micromolar concentration and therefore,
are called TTX-resistant Na+ channels (Zimmer, 2010).
1.1.2.2 Voltage- gated Ca2+ channel
Voltage-gated Ca2+ channels (VGCCs) are key transducers of membrane
potential changes into intracellular Ca2+ transients that initiate various
physiological events, ranging from neurotransmitter release to muscle contraction
(Catterall, et al., 2005b). Voltage-gated Ca2+ channels consist of five subunits
called α1, α2, γ, β, and δ of which α1 constitutes the pore forming subunit
(Figure1.3). The associated subunits have several functions including regulation
of channel trafficking and modulation of current kinetics (Bodi, et al., 2005). The
channel protein forming the α 1 subunit consists of more than 2000 amino acids
(molecular weight ~170 kDa) and contains four homologous domains (I-IV). Each
domain contains six transmembrane segments (S1-S6) and a membrane associated
loop between S5 and S6 segments. The S4 segment of each homologous domain
serves as the voltage sensor for activation; moving outward and rotating under the
influence of the electric field and initiating a conformational change that leads to
the opening of the pore. The S5 and S6 segments and the membrane-associated
pore loop between them form the pore lining of the VGCC (Catterall, 2011; Grant,
2009). Each of the four pore-lining loops (P-I through P-IV) of each domain
contributes a glutamate residue (E) to the pore structure. These conserved residues
(EEEE) in the pore have been shown to be critical for Ca2+ selectivity of the
channel (Sather and McCleskey, 2003). Expression of the α1 subunit is sufficient
9

Figure 1.3 Structure of voltage gated Ca 2+ channel: The α subunit of Ca2+
channel is illustrated together with the β, γ and α 2δ subunits. Roman numerals
indicate the domains of α subunit; segments 5 and 6 are the pore-lining segments
and the S4 helices make up the voltage sensors. Adapted from Catterall, 2011.
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to produce a functional Ca2+ channel, but it displays low expression level,
abnormal kinetics, and voltage dependence (Perez-Reyes, et al., 1989). Studies
have shown that co-expression of α2δ subunit and β subunit enhances the level of
expression and confers more physiological gating properties (Lacerda, et al.,
1991; Singer, et al., 1991).
To date, ten subtypes of VGCCs have been described in mammals (Table
1). These subtypes serve distinct roles in signal transduction and other cellular
functions (Catterall, 2011). The L-type subfamily (or CaV1) of VGCCs initiate
contraction, secretion, regulation of gene expression and integration of synaptic
input in neurons (Minor, Jr. and Findeisen, 2010). The neuronal CaV2 subfamily
which includes the N-type (CaV2.1), P/Q-type (CaV2.2), and R-type (CaV2.3)
channels is responsible for initiation of synaptic transmission at fast synapses
(Catterall, et al., 2005b). The T-type channels (or CaV3) are important for
repetitive firing of action potentials in rhythmically firing cells such as cardiac
cells (Minor, Jr. and Findeisen, 2010; Catterall, 2011).
In cardiac muscle, the two types of VGCCs, the L-type (long lasting) Ca2+
channels and the T-type (transient) Ca2+ channels play an important role in muscle
contraction and automaticity, respectively (Grant, 2009). There are four α1 subunit
variants of the L-type Ca2+ channels: Cav1.1 (α1S), 1.2 (α1C), 1.3 (α1D) and 1.4
(α1F) of which Cav1.2 (α1C) subunit is the cardiac specific L-type Ca2+ channel
subunit (Table 1.1) (Minor, Jr. and Findeisen, 2010).
In the presence of Ca2+, the currents are rapidly inactivated via a
Ca2+/calmodulin-dependent mechanism (Ferreira, et al., 1997). This process is
crucial for limiting Ca2+ entry during long cardiac APs. Moreover, reuptake of
Ca2+ by the sarcoplasmic reticulum (SR) during prolonged depolarization can
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Ca2+
current
type
L

α1
subunits

Conductance,
pS

Activation
threshold

Inactivation
rate

Location and
Functions

References

Cav1.1
Cav1.2
Cav1.3
Cav1.4

25

High

Slow

Bodi, et al.,
2005;
Catterall, et
al., 2005b;
Cens, et al.,
2006.

N

Cav2.1

20

High

Moderate

Excitation
contraction
coupling in
muscle, cardiac
pacemaking,
endocrine
secretion and
neuronal Ca2+
transients
Neurons only;
neurotransmitter
release

P/Q

Cav2.2

10-20

High

Fast

Neurons only;
neurotransmitter
release

R

Cav2.3

-

High

-

Neurons only;
neurotransmitter
release

T

Cav3.1
Cav3.2
Cav3.3

5-10

Low

Fast

Cardiac sinoatrial
node, neurons;
repetitive spiking
and spike activity

Table 1.1 Subunit composition and function of Ca2+ channel types
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Catterall, et
al., 2005b;
Minor, Jr. and
Findeisen,
2010.
Catterall, et
al., 2005b;
Minor, Jr. and
Findeisen,
2010.
Catterall, et
al., 2005b;
Minor, Jr. and
Findeisen,
2010.
Catterall, et
al., 2005b;
Minor, Jr. and
Findeisen,
2010;
Catterall,
2011.

result in the recovery from Ca2+-dependent inactivation, and enable secondary
depolarization (Grant, 2009). The carboxyl termini of L-type Ca2+ channels have
multiple Ca2+ binding sites and Ca2+/calmodulin-dependent kinase activity.
Binding of calmodulin to these domains has been shown to cause Ca2+-dependent
inactivation of L-type Ca2+ channels (Bodi, et al., 2005; Cens, et al., 2006).
Importantly, using Ba2+ as a charge carrier removes the Ca2+-induced inactivation.
In other words, activation of L-type Ca2+ channels in the presence of Ba2+ results
in inward Ba2+ currents that activate rapidly, but inactivate slowly (Ferreira, et al.,
1997).
In comparison to L-type Ca2+ channels, there are three α1 subunit variants
of T-type Ca2+ channels: Cav3.1 (α1G), 3.2 (α1H) and 3.3 (α1I) (Zhang, et al., 2013).
These channels are activated at much more negative membrane potentials
(activation starts at -60 mV), inactivated rapidly, have a small single channel
conductance (<10 pS), and are insensitive to the conventional L-type Ca2+ channel
antagonists dihydropyridines, phenylalkylamines and benzothiazepines (Bodi, et
al., 2005; Zhang, et al., 2013). While L-type Ca2+ channels are important in
maintaining the plateau phase of AP in ventricular cells, both L-type and T-type
Ca2+ channels play a role in generating the AP in cells that are involved in
rhythmic electrical behavior; sinoatrial node and atrioventricular node (Catterall,
et al., 2005b; Bodi, et al., 2005; Zhang, et al., 2013).
1.1.3 Myocardial Ca 2+ handling
The importance of Ca2+ signaling in the heart has been appreciated for
decades. With each heartbeat, Ca2+ concentration in the cytosol of cardiac
myocytes is elevated approximately 10-fold from a resting level of about 100 nM
to ~1 μM (Bodi, et al., 2005). The levels of cytosolic Ca2+ control the activation of
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contractile proteins. In other words, the onset, the duration and the intensity of
myocardial contraction are strictly controlled by intracellular [Ca2+]i. The
electrical activation with the spreading of the AP throughout the heart initiates
contraction by causing a transient increase in cytosolic Ca2+ concentration, leading
to a brief (~400 ms) Ca2+ transient (Bers, 2002).
The AP generates the cytosolic Ca2+ transient via a process called Ca2+induced Ca2+ release (Fabiato, 1983; Eisner, et al., 2013) (Figure 1.4). During this
process, the influx of a small amount of Ca2+ via voltage-gated L-type Ca2+
channels located in the T-tubules, induces Ca2+ release from the SR by activating
ryanodine receptor 2 (RyR2). This leads to a considerable amplification of the
initial Ca2+ influx to a level required for the optimal binding of Ca2+ to the
myofilament protein troponin C in the troponin complex on the thin filament,
which in turn switches on the contractile machinery (Bodi, et al., 2005). The
troponin complex is composed of troponin C (TnC or the Ca2+ binding subunit),
troponin I (TnI, involved in inhibition of actin-myosin interaction in the absence
of Ca2+), and troponin T (TnT which binds the troponin complex to tropomyosin,
another filament protein) in a stoichiometric ratio of 1:1:1 (Gomes, et al., 2002).
The thin (actin) and thick (myosin) filaments slide along each other driven by
ATP hydrolysis resulting in muscle shortening and force production. Relaxation
occurs after 100-200 ms when Ca2+ gradually decays back to diastolic levels. In
this case, tropomyosin is positioned such that actin and myosin cannot interact
leading to the relaxation of cardiac muscle cell (Huke and Knollmann, 2010).
Calcium homeostasis is particularly important in cardiac muscle cells. The
decline in cytosolic Ca2+ concentration is due to termination of Ca2+ release from
the SR (inactivation of RyR2) and rapid removal of Ca2+ from the cytosol. Two
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Figure 1.4 Ca2+-induced Ca2+ release and Ca2+ cycling in a cardiac cell: Ca2+
entry via the L-type Ca2+ channel causes the release of Ca2+ from the SR via RyR
resulting in Ca2+ transient and muscle contraction. Relaxation occurs by the Ca2+
being taken back into the SR by SERCA and pumped out of the cell by NCX. The
inset shows the amplitude of the Ca2+ transient as a function of SR Ca2+ content.
Modified from Eisner, et al., 2013.
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major routes are responsible for Ca2+ removal from the cytosol: the SR Ca2+ATPase (SERCA2a) that uses ATP to pump Ca2+ back into the SR and the
sodium-calcium exchanger (NCX) (Ottolia, et al., 2013) (Figure 1.4). Under
physiologic conditions, NCX removes approximately the same amount of Ca 2+
that entered the cell through L-type Ca2+ channel in order to maintain the cellular
Ca2+ balance (Bridge, et al., 1990). Sarcolemmal Ca2+-ATPase and the
mitochondrial Ca2+ uniport are considered minor players in Ca2+ homeostasis,
although there is accumulating evidence that they can also influence the levels of
Ca2+ in cellular Ca2+ stores and modify excitation-contraction coupling (Dedkova
and Blatter, 2013; Ottolia, et al., 2013).
As mentioned earlier, the amplitude of the Ca2+ transient determines the
level of myofilament activation, and therefore the magnitude of contraction. The
two main factors that determine the amount of Ca2+ released from the SR and the
amplitude of the Ca2+ transient are: the amplitude of the L-type Ca+2+ current
(Trafford, et al., 2001), and the Ca2+ concentration in the SR (Shannon, et al.,
2000). The SR Ca2+ concentration can be increased by the stimulation of
SERCA2a activity and prolongation of the duration of the AP, and decreased by
the stimulation of NCX working in the forward mode (Ottolia, et al., 2013).
In general, any alternation in Ca2+ flux results in an overall change in
contractility (Ottolia, et al., 2013). For example, a persistent reduction in cellular
Ca2+ efflux, not matched by a decrease in Ca2+ influx, results in an increased
cellular Ca2+ which will accumulate in the SR rather than the cytoplasm. The
increased amount of Ca2+ in SR typically results in larger Ca2+ transients and
therefore contractility (Bassani, et al., 1995; Shannon, et al., 2000). Conversely,
an increase in Ca2+ efflux will deplete SR stores and depress contractility.
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Under in vivo conditions, the main modulator of Ca2+ transient amplitude is
β-adrenergic stimulation that is mediated by cAMP/PKA which has three main
actions on Ca2+ signaling (Catterall, 2011). First, it stimulates the L-type VGCCs
to increase the amount of Ca2+ that enters during each AP. Second, it
phosphorylates the protein phospholamban (PLB) to reduce its inhibitory effect on
SERCA2a pump, which is then able to increase the luminal Ca 2+ concentration so
that more Ca2+ is released from the SR. Third, cAMP/PKA phosphorylates the
RyR2, thereby enhancing its ability to release Ca2+ (Frank, et al., 2003). Therefore,
the activation of both L-type Ca2+ channel and SERCA2a leads to a substantial
increase in the amplitude of Ca2+ transients.
1.1.4 Role of the Na+/Ca2+ exchanger in calcium homeostasis
The NCX is a plasma membrane transport protein and is considered as the
main extrusion pathway for Ca2+ from ventricular myocytes. It is directly involved
in the regulation of excitation-contraction coupling by means of modulating Ca2+
efflux, SR Ca2+ load (Bers, et al., 1989; Bers and Weber, 2002), SR Ca2+ release
(Litwin, et al., 1998) and Ca2+ spark frequency (Goldhaber, et al., 1999). This is
likely to contribute, alongside other proteins such as SR Ca 2+-ATPase and
calmodulin, as an effective buffering mechanism to maintain steady-state Ca2+
flux during short term Ca2+ transients.
The NCX can extrude intracellular Ca2+ across the cell membrane against
its chemical gradient by using the downhill gradient of Na+. It is widely accepted
that the stoichiometry of this ion exchange occurs such that while one positive
charge (Ca2+) go out, three positive charges (3 Na+) are taken up by the cell (Bers,
2002; Bers and Weber, 2002). Therefore, NCX activity is electrogenic. Under
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resting conditions, NCX functions in forward mode. However, NCX is
bidirectional and can also mediate Ca2+ entry and outward movement of Na+. This
is referred to as the reverse mode. The direction and amplitude of the NCX current
is governed by Na+ and Ca2+ gradients across the cell membrane, as well as, the
membrane potential. The most recognized action of NCX is its Ca2+ removal in the
forward mode at membrane voltages less than the equilibrium potential, which
under physiological conditions, is about -50 mV to -60 mV (Reuter, et al., 2005;
Ottolia, et al., 2013).
Recently, the molecular structure of NCX protein has been elucidated
(Figure 1.5) (Morad, et al., 2011). It has been shown that mammalian NCX forms
a multigene family of homologous proteins comprising three isoforms. Sodiumcalcium exchanger 1 (NCX1) was the first NCX cloned and is highly expressed in
cardiac muscle and brain and to a lesser extent in many other tissues (Hilgemann,
et al., 2013; Lytton, 2007). Sodium-calcium exchanger 2 (NCX2) is expressed
primarily in the brain (Canitano, et al., 2002), while sodium-calcium exchanger 3
(NCX3) is expressed in the brain, as well as, skeletal tissue (Canitano, et al., 2002;
Lytton, 2007).
The cardiac NCX1 consists of 970 amino acids with a molecular weight of
about 110 kDa. Although recent crystal structure of NCX1 strongly supports the
presence of 10 transmembrane segments (Ren and Philipson, 2013), biochemical
analysis has indicated the presence of nine transmembrane segments, and a large
hydrophilic group with conserved regions between transmembrane segments five
and six. The N- and C-termini are located on the external and internal sides,
respectively (Shigekawa and Iwamoto, 2001; Ren and Philipson, 2013).
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Figure 1.5 Hypothetical functional organization of Na +/Ca2+ exchanger: The
critical residues T731, T723, and S722 are important for cAMP-dependent
regulation. Detailed structures have only been determined for the Ca2+-binding
domains β1 and β2. The detailed arrangement and function of all other
components, including the α-helices of the transmembrane-spanning (top) and αcatenin-like (αCat) domains and the unstructured linker sequences (S1, S2, A/BCDEXF) remain to be ascertained. Adapted from Morad, et al., 2011.
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Similar to Ca2+ channels, NCX is also regulated allosterically by [Ca2+]i
(Ottolia, et al., 2013). In addition, the activity of NCX is regulated by the
signaling lipid phosphatidylinositol-4,5-bisphosphate (PIP2) (Hilgemann and Ball,
1996), free radicals, pH and temperature, as well as, PKA (Schulze, et al., 2003;
Wei, et al., 2003) and PKC (Blaustein and Lederer, 1999; Iwamoto, et al., 1996).
However, the physiological significance of these factors as in vivo regulators of
NCX remains to be established.
1.2. The endocannabinoid system
1.2.1 Introduction
The psychoactive properties of the plant Cannabis sativa have been known
to man for thousands of years. The popularity of marijuana, one of the most
commonly used drugs of abuse, reflects its powerful effects on sensory
perception, learning and anxiety. Non-psychoactive uses of marijuana include
pain relief, muscle relaxation, attenuation of nausea and vomiting and treatment of
multiple sclerosis (Pertwee, 2001; Howlett, 2002; Smith, 2004). Despite its use for
centuries, it is only during the last few decades that the biological basis of the
effects of marijuana and its bioactive ingredients, collectively called cannabinoids,
has begun to unfold (Kunos, et al., 2000). In the 1960s, Δ9-tetrahydrocannabinol
(THC) was discovered as the primary psychoactive component of Cannabis sativa
(Mechoulam and Gaoni, 1965; Mechoulam, et al., 1995). However, it is important
to note that Cannabis contains over 60 chemicals with closely related structures.
Among them, THC, cannabinol and cannabidiol are the most commonly studied
cannabinoids (Di Marzo, V, 2006).
The isolation of THC paved the way for the development of THC-based
ligands and led to the discovery of cannabinoid receptors. The first cannabinoid
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binding site in rat brain was identified in 1988 (Devane, et al., 1988), and the
receptor was cloned later in 1990 (Matsuda, et al., 1990). This receptor was
named cannabinoid receptor 1 (CB1). The second receptor, cannabinoid receptor 2
(CB2), was discovered shortly after (Munro, et al., 1993).
In earlier studies, the presence of opiate receptors in the mammalian brain
(Pert and Snyder, 1973) has led to the discovery of endogenous opioid peptides.
Therefore, several groups have searched for endogenous ligands that mimic the
action of Cannabis. Only in the early nineties, similar to the opioid system,
cannabinoid receptors were found to have endogenously produced ligands
(Devane, et al., 1992). These are now called the endocannabinoids.
The endocannabinoid system (ECS) is a complex and ubiquitously
expressed signaling system which includes several neuromodulatory lipids
(endocannabinoids), their receptors and a set of enzymes that synthesize and
degrade endocannabinoids. The ECS has been identified in most human organs
and tissues, and has important regulatory roles in a wide range of normal and
pathological processes, such as pain, energy homeostasis, fertility, immune
response and behavior (Rodriguez de, et al., 2005; De and Di, V, 2009a).
1.2.2 Endocannabinoids
Endocannabinoids belong to a family of polyunsaturated fatty acid-based
compounds synthesized from the lipid precursors in the plasma membranes of
virtually all types of cells ranging from neurons and endocrine cells to skeletal
muscle fibers and cardiomyocytes (Pacher, et al., 2006). They are implicated in a
wide variety of physiological processes including memory, immunity, sleep, pain
sensation, perception, reproduction (Martin, et al., 1999) and cardiovascular
functions (Clapper, et al., 2006; Sterin-Borda, et al., 2005; Randall and Kendall,
21

1997). To date, the two most extensively studied endocannabinoids are Narachidonoylethanolamine (AEA), also known as anandamide (from the Sanskrit
‘ananda’ for happiness, joy or enjoyment), and its glycerol ester analogue 2arachidonoylglycerol (2-AG). Anandamide was first described in 1992 (Devane,
et al., 1992). However, 2-AG was discovered as the second endocanabinoid a few
years later (Mechoulam, et al., 1995; Sugiura, et al., 1995) (Figure 1.6).
In addition to AEA and 2-AG, other endocannabinoids with similar fatty
acid-based chemical structures were also identified during the last decade,
including, 2-arachidonylglycerol ether (noladin ether) (Hanus, et al., 2001), Narachidonoyl-dopamine (NADA) (Bisogno, et al., 2000), and virodhamine (Porter,
et al., 2002) (Figure 1.6). Virodhamine has a very similar structure to AEA, but
opposite orientation around the arachidonic acid (AA)-ethanolamine bond (Porter,
et al., 2002). Likewise, noladin ether and 2- AG are structurally similar (Figure
1.6). However, pharmacological characterization of these chemicals has not been
well established.
Anandamide belongs to a group of chemicals termed N-acylethanolamines
(NAEs). Other NAEs are not usually considered as endocannabinoids but are
produced by the same enzymes that synthesize AEA. In recent years, several
studies have shown that these chemicals play a role in vascular control (Ho, et al.,
2008), food intake, energy balance (Borrelli and Izzo, 2009) and neuroprotection
(Hansen, et al., 2000; Hansen, 2010). Two of these NAEs, oleoylethanolamide
(OEA) and palmitoylethanolamide (PEA) have been extensively investigated as
they are present at higher concentration than the endocannabinoids in many
mammalian tissues (Alexander and Kendall, 2007; Lambert and Muccioli, 2007)
(Figure 1.7).
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Figure 1.6 Chemical structures of the proposed endocannabinoids. Adapted
from Di Marzo, 2009
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1.2.3 Endocannabinoid receptors
As mentioned earlier, to date, at least two endocannabinoid receptors have
been identified and cloned based on their pharmacological properties and gene
structure. The CB1 receptors are principally located in the central nervous system,
where they are highly abundant and appear to participate in negative retrograde
signaling (Matsuda, et al., 1990; Mackie, 2008). In addition, they are found in
several peripheral tissues including the heart and the vasculature (Ishac, et al.,
1996; Bonz, et al., 2003; Liu, et al., 2000). The CB2 receptors, on the other hand,
are expressed primarily in the immune system (Munro, et al., 1993) and
hematopoietic cells (Valk and Delwel, 1998), but recently their presence in the
brain (Van, et al., 2005), liver (Mallat and Lotersztajn, 2008; Mackie, 2008),
myocardium (Montecucco, et al., 2009; Defer, et al., 2009), vascular endothelial
and smooth muscle cells (Rajesh, et al., 2007), have also been demonstrated. Both
receptors are G protein-coupled receptors (GPCRs) with seven transmembrane
spanning domains (Howlett, et al., 1990). Most of the G proteins linked to the
cannabinoid receptors are inhibitory proteins (Gi/o). They are sensitive to pertussis
toxin (PTX) and inhibit adenylyl cyclase (AC) activity and thus, inhibit the
formation of cAMP (Pertwee, 2006). However, coupling of cannabinoid receptors
to PTX-insensitive Gq protein has also been reported in recent studies (Straiker, et
al., 2002; McIntosh, et al., 2007).
The CB1 receptor can be activated by both AEA and 2-AG, although 2-AG
is more potent, and AEA is often considered to be a partial agonist (Hillard,
2000). Similarly, both endocannabinoids are agonists of CB2 receptor, although
again 2-AG is more potent. Both AEA (KD values for CB1 and CB2 receptors are
61-543 nM and 279-1940 nM, respectively) and 2-AG (KD values for CB1 and
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CB2 receptors are 58-472 nM and 145-1400 nM, respectively) have greater
affinities for CB1 receptor than CB2 receptor (Munro, et al., 1993; Pertwee, 2006;
Pertwee, et al., 2010). It appears that the selectivity of endocannabinoids varies
significantly. For example, the endocannabinoid noladin ether is a selective CB 1
receptor agonist, while virodhamine is a partial CB2 agonist and a CB1 receptor
antagonist. On the other hand, NADA appears to be a selective agonist for CB1
receptor (Pertwee, et al., 2010; Pertwee and Ross, 2002).
1.2.4 Synthesis and metabolism of anandamide
Endocannabinoids are synthesized predominantly via the cleavage of
membrane phosphoglyceride precursors (Bisogno, 2008). As the endocannabinoid
precursors are physiological chemical constituents of cell membranes, it is the
anatomical location of endocannabinoid synthesizing enzymes and receptors that
dictate their activity and therefore, their physiological roles in cellular
environments (Di, Marzo, et al., 2007). Endocannabinoids are often referred to as
signaling molecules which are synthesized “on demand” and in neurons, at least,
endocannabinoids are synthesized and released very rapidly (within tens of
milliseconds) upon stimulation (Alger and Kim, 2011).
As mentioned earlier, the biosynthetic pathway for AEA is thought to
involve the breakdown of pre-formed arachidonoyl phospholipids in the cell
membrane (Figure 1.8). It was shown that the primary route for AEA biosynthesis
is the formation of N-arachidonoyl phosphatidylethanolamine (NAPE) (Hiley,
2009) which is produced by the transfer of AA from phospholipids to the nitrogen
atom of phosphatidylethanolamine. Subsequently, it is transformed into AEA via
multiple pathways, the most direct of which is catalyzed by Ca 2+-sensitive NAPE-
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Figure 1.8 Mechanisms of anandamide formation and deactivation: The
formation of AEA is thought to include the synthesis of the AEA precursor Narachidonoyl phosphatidylethanolamine (NAPE) catalyzed by the enzyme Nacyltransferase and then the cleavage of NAPE to yield AEA, catalyzed by
phospholipase D (upper panel). AEA can be internalized by cells through a high
affinity transport mechanism; the endocannabinoid transporter. Once inside the
cell, it can be hydrolyzed by FAAH to yield arachidonic acid and ethanolamine
(lower panel). Modified from Piomelli, 2003.
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selective phospholipase D (NAPE-PLD) (De Petrocellis and Di Marzo, 2009a).
This enzyme catalyzes the hydrolysis of the bond between phosphate and
ethanolamine resulting in the formation of AEA and phosphatidic acid.
Endocannabinoid signaling is terminated by a rapid clearance from the
extracellular milieu (half-life is seconds to minutes) (De Petrocells, et al., 2004).
Studies suggest that following cannabinoid receptor activation, AEA is taken up
by cells via a facilitated transport mechanism mediated by a putative anandamide
membrane trasporter (AMT) (Bari, et al., 2006; Piomelli, 2003) followed by
intracellular degradation. Although data from several biochemical and
pharmacological studies support the existence of an AMT, this is a controversial
topic, and the structure of AMT protein remains to be identified at the molecular
level (De Petrocellis, et al., 2004). Currently, it is well established that AEA is
predominantly degraded in the cytosol under the action of FAAH to ethanolamine
and AA (Hiley, 2009; Deutsch and Chin, 1993; Cravatt, et al., 1996). On the other
hand, 2-AG is predominantly broken down by a specific monoacylglycerol lipase
(MAGL) (Vandevoorde and Lambert, 2005). In vitro experiments indicate that
endocannabinoids

are

also

substrates

for

oxidative

metabolism

via

cyclooxygenase (Fowler, 2007) and lipoxygenase (Kozak, et al., 2002) pathways.
Fatty acid amide hydrolase was identified in 1996 (Cravatt, et al., 1996). It
has multiple substrates, but exhibits specificity for the long-chain amides of
ethanolamine (Schmid, et al., 1985). There are two isoforms of FAAH, FAAH-1
and FAAH-2, which share approximately 20 % DNA sequence homology,
although, the catalytic site is relatively well conserved (Wei, et al., 2006a). The
two isoforms are differentially expressed across tissues. In human kidney, liver,
lung and prostate both isoforms are expressed. However, only FAAH-1 levels are

28

high in human brain, small intestine and testis. FAAH-2 is predominantly
expressed in the heart (Wei, et al., 2006a). It is important to note that the two
isoforms have different substrate specificity, with FAAH-1 having significantly
greater hydrolytic activity on AEA than FAAH-2 (rates of hydrolysis in
nmol/min.mg are 17±1 and 0.46±0.04, respectively) (Wei, et al., 2006a). Due to
the pharmacological implication of modulating endocannabinoid levels, in recent
years, several inhibitors have been synthesized (Fowler, et al., 2001). For
example, URB597, JP104, OL-92 and OL-135 are potent inhibitors of FAAH
(Michaux, et al., 2006; Min, et al., 2011). However, these inhibitors differ in their
selectivity. While JP104 is a potent inhibitor of both FAAH-1 and FAAH-2 (Wei,
et al., 2006b), URB597 is more potent at FAAH-2 (Piomelli, et al., 2006).
FAAH is a membrane bound enzyme (McKinney and Cravatt, 2005) and is
thought to form homodimers (Bracey, et al., 2002). The location and structure of
FAAH may allow the hydrolysis of AEA within the close vicinity of plasma
membrane (McKinney and Cravatt, 2005). Indeed, the rate of AEA hydrolysis in
tissues from FAAH knockout mice is 50-100 fold reduced, and AEA
concentrations in the brain (Cravatt, et al., 2001; Lichtman, et al., 2002) and liver
(Tourino, et al., 2010) are elevated significantly.
In recent years, FAAH has emerged as a target for modulating
endocannabinoid signaling (Ahn, et al., 2008) with a therapeutic potential in
anxiety, pain and various inflammatory disorders (Cravatt, et al., 2001; Cravatt, et
al., 2004). In the heart, FAAH plays a key role in controlling endocannabinoidinduced myocardial tissue injury in pathological conditions associated with acute
oxidative stress (Mukhopadhyay, et al., 2011). It was found that AEA induced
enhanced cell death in human cardiomyocytes that were pretreated with FAAH
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inhibitor, and enhanced sensitivity to reactive oxygen species (ROS) generation in
inflammatory cells of FAAH knockouts, all of which suggest a role for FAAH in
controlling tissue injury (Mukhopadhyay, et al., 2011).
1.2.5 Cellular and molecular mechanisms of endocannabinoid actions
1.2.5.1 Signal transduction mechanisms
Signal transduction through CB1 and CB2 receptors is mediated by Gprotein (Gi/o) which couples negatively to AC and thus, inhibits cAMP generation.
Modulation of intracellular cAMP concentration regulates PKA phosphorylation,
and thereby results in major changes in cAMP-dependent signal transduction
pathway (Demuth and Molleman, 2006). In fact, the first characterized CB1
receptor signal transduction response was the inhibition of AC by micromolar
concentration of THC in neuroblastoma cells (Howlett and Fleming, 1984).
Subsequent studies demonstrating the blockade of this response by PTX treatment
suggested that Gi/o type G-proteins are involved (Howlett, et al., 1986). Typical
Gi/o -mediated intracellular events coupled to CB1 activation are the inhibition of
VGCCs of most types, including P/Q (Twitchell, et al., 1997), N (Wilson, et al.,
2001) and L-type (Gebremedhin, et al., 1999; Straiker, et al., 1999) channels and
the stimulation of potassium channels such as KIR channels (McAllister, et al.,
1999) and mitogen-activated protein kinase (MAPK) (Derkinderen, et al., 2001).
In the central nervous system, the role of endocannabinoids in retrograde
signaling has been well established. It has been shown that the activation of
presynaptic CB1 receptors controls the release of several neurotransmitters, such
as glutamate and GABA (Lovinger, 2008; Foldy, et al., 2006). Synthesis of
endocannabinoids occurs following the release of excitatory neurotrasmitters and
their diffusion outside the synaptic region. The action of glutamate on its receptor
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in the postsynaptic membrane leads to the release of intracellular Ca 2+ and the
opening of VGCCs. An elevated level of Ca2+ activates the enzymes responsible
for endocannabinoid synthesis from lipid precursors. Anandamide and/ or 2-AG
are released and following retrograde diffusion in the synaptic cleft, presynaptic
CB1 receptors are activated. This activation results in the inhibition of VGCCs or
activation of K+ channels resulting in decreased intracellular Ca2+ concentration,
preventing further neurotransmitter release from the presynaptic terminal
(Vaughan and Christie, 2005).
Recent studies indicate that the interaction of cannabinoids with G proteins
is not limited to Gi/o subtype. Evidence suggests that CB1 receptors can also
interact with Gs protein under conditions of PTX treatment that prevents the
receptor’s interaction with Gi/o protein (Howlett, et al., 1986). CB2 receptors, in
contrast, do not seem to couple to Gs subtype, suggesting further differences
between CB1 and CB2 receptor signaling (Glass and Felder, 1997). For example,
stimulation of cAMP accumulation by HU-210 (the synthetic analogue of THC)
and CP 55,940 (a highly potent cannabinoid agonist) was observed after PTX
treatment of Chinese hamster ovary (CHO) cells expressing the human CB1 but
not CB2 receptors (Calandra, et al., 1999; Glass and Felder, 1997). In addition to
the dual coupling of cannabinoid receptors to Gs and Gi/o proteins, the presence of
distinct isoforms of AC in different cellular preparations has also been shown to
contribute to the diversity of cannabinoid actions. To date, nine isoforms of AC
have been identified (AC-I, AC- II, AC-III, AC-IV, AC-V, AC-VI, AC-VII, ACVIII and AC-IX) (Demuth and Molleman, 2006). The isoform AC-I is found
mainly in the brain while the isoforms AC-V and AC-VI are highly expressed in
brain and heart. When monkey kidney (COS-7) cells expressing exogenous CB1
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receptors were transfected with each AC isoform in turn and stimulated with the
cannabinoid agonists HU-210 and WIN 55,212-2, the isoforms AC-I, AC-V, ACVI and AC-VIII were shown to be inhibited, whereas, AC-II, AC-IV and AC-VII
were stimulated by CB1 receptor activation (Rhee, et al., 1998). Collectively, all
these results suggest that CB1 receptors may be dually coupled to both Gs and Gi/o
proteins in some systems. It is likely that the contrasting effects of cannabinoids
on AC activity could be attributed to the specific isoform present in different
cellular preparations. However, physiological significance of these diverse
coupling mechanisms of cannabinoid receptors to various G-proteins needs further
investigation.
Another effect described for both CB1 and CB2 receptors is the modulation
of intracellular Ca2+ concentration. CB1 receptor agonists, including AEA and 2AG, were shown to directly stimulate the hydrolysis of PIP 2 by phospholipase C
(PLC-β) with subsequent release of IP3 followed by Ca2+ mobilization from the
endoplasmic reticulum via either Gq-mediated or Gi/o-mediated mechanisms
(Sugiura, et al., 1996; Ho, et al., 1999; Lauckner, et al., 2005). In NG108-15 cells
(Sugiura, et al., 1996) and in cultured cerebellar granule cells (Netzeband, et al.,
1999), cannabinoid receptor agonists have been shown to increase intracellular
Ca2+ concentration by releasing Ca2+ from IP3-sensitive stores. It appears that these
effects of cannabinoids are sensitive to CB1 antagonism and PTX treatment
(Sugiura, et al., 1996; Netzeband, et al., 1999).
Activation of CB2 receptors has also been shown to increase intracellular
Ca2+ levels, although, CB2 receptor-mediated Ca2+ responses are less pronounced
than the potent CB1 receptor-mediated effects (Felder, et al., 1995; Zoratti, et al.,
2003). In calf pulmonary endothelial cells, Zoratti et al., observed CB2-dependent
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increase in cytosolic Ca2+ via activation of PLC and a subsequent release of Ca2+
from IP3-sensitive stores (Zoratti, et al., 2003).
However, in some other experiments, cannabinoid-induced Ca2+ release
has been shown to be associated with the release of nitric oxide (NO). For
example, in cultured human arterial endothelial cells, AEA evoked an increase in
intracellular Ca2+ concentration in an SR141716A-sensitive manner. This increase
was shown to be coupled to NO release (Fimiani, et al., 1999). In human umbilical
endothelial cells, intracellular Ca2+ increase was insensitive to PTX and only
marginally blocked by SR141716A. Anandamide also significantly increased NO
synthase activity (Mombouli, et al., 1999). Collectively, these results suggest that
CB1 receptor-dependent and independent increase in intracellular Ca2+ and
subsequent NO production may account for some of the vasodilator actions of
AEA. However, the increase in intracellular Ca2+ concentration seems at odds
particularly with cannabinoid inhibition of neuronal excitability which is thought
to be caused by VGCCs inhibition. In addition to NO synthase activation
mechanism, it is possible that subcellular localization of signaling pathways could
explain this paradox. For example, it may be envisaged that Ca2+ release from
intracellular stores in excitable cells can be inhibitory through activation of Ca 2+dependent K+ channels, leading to hyperpolarization. This would then prevent the
activation of VGCCs and large Ca2+ influx (Demuth and Molleman, 2006).
In addition to the second-messenger pathways described above, functional
modulation of various ion channels and receptors by endocannabinoids has also
been demonstrated. One of these ion channels is the transient receptor potential
(TRP) channel which constitutes a large and a functionally versatile family of
cation-permeable transmembrane proteins. To date, vanilloid receptors (TRPV1)
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are the best characterized TRP channels. They are primarily heat receptors
expressed in sensory neurons and their activation leads to Ca2+ entry and
neurotransmitter release (Demuth and Molleman, 2006).
The realization that AEA is chemically similar to capsaicin, an agonist of
TRPV1 channel (Di Marzo, et al., 1998) lead to the discovery that AEA can serve
as an agonist not only on cannabinoid receptors but also on TRPV1 channels. For
example, the TRPV1 receptor-mediated vasodilatory effect of AEA in rat and
guinea pig arteries has been shown to be blocked by the TRPV1 antagonist
capsazepine (Zygmunt, et al., 1999). Similarly, application of AEA (10 µM)
causes activation of TRPV1 receptors in cultured cells transfected with rat or
human TRPV1 receptors or in neurons of neonatal rat dorsal root ganglia
(Zygmunt, et al., 1999; Smart, et al., 2000; Ross, et al., 2001). Furthermore, the
ability of AEA to stimulate TRPV1 receptors appears to be regulated by the state
of activation of protein kinase A and protein kinase C (Premkumar and Ahern,
2000; Di Marzo, et al., 2002). In this context, it is important to note that colocalization of cannabinoid receptors and TRPV1 channels have made the
interpretation of some experiments difficult (Hermann, et al., 2003; Di Marzo and
Cristino, 2008).
In recent years, it has been shown that endocannabinoids are ligands for
peroxisome proliferator-activated receptors (PPARs) (O'Sullivan, et al., 2005;
Lenman and Fowler, 2007). PPARs are nuclear transcription factors that are
highly expressed in metabolically active tissues such as liver, adipose, skeletal
muscle and heart (Stienstra, et al., 2007). These receptors play key roles in
regulating cellular differentiation, lipid metabolism and inflammation (Glass and
Ogawa, 2006). In the heart, these receptors can modulate myocardial lipid
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metabolism, as well as, glucose and energy homeostasis (Lee, et al., 2011).
Cannabinoid-related agonists identified to date for PPARs include AEA, 2-AG,
OEA, THC, NADA and cannabidiol (Fu, et al., 2005; O'Sullivan, et al., 2009a;
O'Sullivan, et al., 2009b; O'Sullivan, et al., 2005; Rockwell, et al., 2006). In some
studies, it has been shown that the anti-inflammatory effects of AEA and 2-AG
are sensitive to PPARs antagonism (Rockwell and Kaminski, 2004; Rockwell, et
al., 2006). In addition, a study carried by O’Sullivan et al., has shown that the
endocannabinoid AEA, activates PPARs in rat aorta, leading to NO-dependent
relaxation (O'Sullivan, et al., 2009a). Activation of PPARs in the heart by some
endocannabinoids may represent a novel mechanism for endocannabinoid
regulation of the cardiovascular system (O'Sullivan, et al., 2009a).
Further to these well-recognized endocannabinoid targets, emerging
evidence demonstrates that, beyond their receptor-mediated effects, AEA and
other cannabinoid-receptor ligands are able to alter the functional properties of
ligand-gated ion channels in a cannabinoid receptor-independent manner (Oz,
2006). Direct effects of endocannabinoids include modulation of the function of
serotonin type 3 (5-HT-3) receptors (Oz, et al., 2002), nicotinic acetylcholine
receptors (Jackson, et al., 2008; Oz, et al., 2004a; Butt, et al., 2008), muscarinic
acetylcholine receptors (Christopoulos and Wilson, 2001) and glycine receptors
(Hejazi, et al., 2006; Xiong, et al., 2012).
In addition to ligand-gated ion channels, endocannabinoids have been
shown to interact with several classes of voltage-gated ion channels in a
cannabinoid receptor-dependent and independent manner (Oz, 2006). Evidences
for both mechanisms are discussed in the following section.
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1.2.5.2 Receptor-dependent and independent effects of endocannabinoids on
voltage-gated ion channels
1.2.5.2.1 Effects on Na + channels
Endocannabinoids have been shown to inhibit directly the functions of
voltage-gated Na+ channels (VGSCs) in neuronal structures. In an earlier study,
Nicholson et al., have demonstrated the ability of AEA and WIN 55, 212-2 to
inhibit VGSCs (activated by veratridine) in mouse synaptosomes (Nicholson, et
al., 2003). The cannabinoids also blocked the veratridine-induced release of
neurotransmitters from synaptosomes including GABA and glutamate. The CB1
antagonist AM251 did not attenuate Na+ channel inhibition (Nicholson, et al.,
2003). In addition, AEA and WIN 55, 212-2 were able to displace the binding of
[3H]batrachotoxinin A 20-α-benzoate ([3H]BTX-B) to VGSCs (Nicholson, et al.,
2003). Together, the data suggest that cannabinoids can directly modulate the
activity of VGSCs, depressing synaptic transmission in the brain, and in turn,
reduce both excitatory and inhibitory neurotransmitter release.
In rat dorsal root ganglion neurons, AEA inhibited both tetrodotoxin
(TTX)-sensitive and TTX-resistant Na+ currents in a concentration-dependent
manner. This inhibition was not reversed by the CB1 antagonist AM251, the CB2
antagonist AM630 and the vanilloid receptor antagonist capsazepine, suggesting a
direct action of AEA on Na+ channels (Kim, et al., 2005). In a study carried out by
Duan et al., 2-AG and NADA were found to modify the binding of [3H]BTX-B to
VGSCs of mouse brain and inhibit their function in vitro (Duan, et al., 2008).
These effects were not influenced by the application of the CB1 receptor
antagonist AM251. It was concluded that 2-AG and NADA directly inhibit Na+
channel function, which contributes to the suppression of neuronal excitation and
inhibition of neurotransmitter release in the presynaptic membranes (Duan, et al.,
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2008). A recent study has shown that AEA blocks sensory neuronal Na+ channel
isoform Nav1.7 in stably transfected human embryonic kidney (HEK) 293 cells
(Theile and Cummins, 2011). However, inhibition of VGSCs is not limited to
endocannabinoids. Other members of NAEs family have also been shown to act
on Na+ channels. In mouse brain synaptosomes, OEA inhibited the binding of
[3H]BTX-B. In addition, OEA at a concentration of 10 μM, decreased peak Na+
currents in cultured N1E-115 neuroblastoma cells in a voltage-dependent manner,
and caused a hyperpolarizing shift in the inactivation curve of the channel. In this
respect, the effect of OEA reflects the actions of local anesthetic drugs used as
antiarrhythmic agents. Therefore, OEA is likely to regulate cardiac cell
excitability (Nicholson, et al., 2001). Indeed, a recent study in neonatal
cardiomyocytes showed that the two NAEs, SEA and OEA, influenced the
voltage-dependence of activation, inactivation, and the kinetics of Na+ currents
(Voitychuk, et al., 2012). These effects may in part be responsible for the decrease
in cardiomyocytes’ excitability by these lipids under normal as well as
pathological conditions. Interestingly, the effects of endocannabinoids such as
AEA and 2-AG on cardiac Na+ channels have not been reported.
1.2.5.2.2 Effects on Ca 2+ channels
In earlier studies it has been shown that AEA, WIN 55, 213-2, and CP 55,
940 act via CB1 receptors to decrease Ca2+ influx in NG 108-15 cells (Mackie and
Hille, 1992; Mackie, et al., 1993). This effect was blocked by pretreatment with
PTX, demonstrating its mediation by G i/o protein, and was independent of cAMP
pathway, as the response was not reversed by the addition of 8-Bromo-cAMP
(Mackie and Hille, 1992; Mackie, et al., 1993). Similarly, in rat superior cervical
ganglion neurons transfected with CB1 receptors, WIN55,212-2 and CP55,940
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inhibited N-type Ca2+ currents in a PTX-sensitive manner (Pan, et al., 1996).
Another study in rat striatal neurons indicated that WIN55,212-2 inhibited
corticostriatal glutamatergic synaptic transmission in an SR141716A-and a PTXsensitive manner. The inhibition of N-type Ca2+ channels was thought to mediate
this effect as ω-conotoxin abolished the WIN55,212-2-mediated synaptic
inhibition (Huang, et al., 2001). On the other hand, another study has reported the
direct effect of AEA (1-10 µM) on N-type VGCCs in superior cervical ganglion
neurons that do not express endogenous cannabinoid receptors. The effect
persisted in the presence of either SR141716A or PTX. However, 2-AG (10 µM)
did not have similar effects (Guo and Ikeda, 2004).
In cultured rat hippocampal neurons, AEA, WIN55,212-2 and CP55,940
inhibited N- and P/Q type Ca2+ currents in an SR 141716A- and PTX-sensitive
manner (Twitchell, et al., 1997; Shen and Thayer, 1998). In the presence of
SR141716, Win55,212-2 (nanomolar concentrations) inhibited N-Type VGCCs
by only 2 % (Shen and Thayer, 1998). Interestingly, at concentrations higher than
1µM, Win55,212-2 inhibited N-Type VGCCs in a manner independent of
SR141716A. In addition, the inactive stereoisomer WIN55,212-3 (micromolar
concentrations) also inhibited Ca2+ currents in an SR141716A-insensitive manner.
Collectively, these findings indicate that at micromolar concentrations, the effects
of WIN55,212-2 are not mediated by CB1 receptors, suggesting a direct effect of
cannabinoids on N-type VGCCs.
In addition to neuronal Ca2+ channels, modulation of T-type Ca2+ channels
by endocannabinoids has also been demonstrated in several studies. Previously,
direct inhibitory effect of AEA on T-type VGCCs has been reported (Chemin, et
al., 2001). T-type VGCCs are known to contribute to pacemaker activity in the
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central nervous system and in the heart. All three cloned T-type VGCCs (α1H, α1I
and α1G) which were transfected in HEK 293 and CHO cells and endogenously
expressed in NG 108-15 cells, were inhibited by AEA in the concentration range
of 0.01-10 µM (Chemin, et al., 2001). This inhibitory effect was not mimicked by
synthetic cannabinoids including WIN55,212-2, CP55,940 and HU-210, and was
not blocked by SR141716A (Chemin, et al., 2001). Notably, AEA continued to
inhibit T-type VGCCs in excised inside-out patches of HEK-293 cells (Chemin, et
al., 2001) suggesting that the effect of AEA is membrane delimited, and is not
mediated by second messenger pathway. Furthermore, the effect of AEA was
mimicked by methanandamide (metAEA), the metabolically stable analogue of
AEA (Abadji, et al., 1994), indicating that the metabolic products of AEA
hydrolysis, such as AA and ethanolamine, are not involved in the inhibition of Ttype Ca2+ currents (Chemin, et al., 2001). From these observations it was
suggested that AEA directly inhibits T-type VGCCs by acting on the cell
membrane. A more recent study supporting these finding was carried out by Ross
et al. (Ross, et al., 2009). Human recombinant T-type VGCCs expressed in HEK
293 cells and native mouse T-type VGCCs were used to test the effect of the
endocannabinoid NADA. The results of this study have shown that NADA
robustly inhibits both human recombinant and native mouse T-type VGCCs (The
rank order of potency was (pEC50) of CaV3.3 (6.45) ≥ CaV3.1 (6.29) > CaV3.2
(5.95)) (Ross, et al., 2009). These results were broadly similar to those previously
reported for AEA (Chemin, et al., 2001; Chemin, et al., 2007).
Besides N-type and T-type Ca2+ channels, L-type Ca2+ channels have also
been shown as target proteins for endocannabinoids. In cat cerebral arterial
smooth muscle cells, it was found that activation of CB1 receptors inhibits L-type
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VGCCs, resulting in cerebral vasodilation (Gebremedhin, et al., 1999).
WIN55,212-2-and AEA induced concentration-dependent inhibition of peak Ltype Ca2+ current. The inhibitory effects of both ligands were abolished by PTX
pretreatment and by the CB1 antagonist SR141716A. In addition, both
WIN55,212-2 and AEA produced concentration-dependent relaxation of preconstricted cerebral arterial segments that was abolished by SR141716A
(Gebremedhin, et al., 1999). These findings suggest that CB1 receptor and its
endogenous ligand may play an important role in the regulation of cerebral arterial
tone by modulating the influx of Ca2+ through L-type VGCCs (Gebremedhin, et
al., 1999). Furthermore, in isolated rat ventricular myocytes, AEA (1, 10 and 100
nM) caused a concentration-dependent inhibition of L-type Ca2+ current and
shifted the current-voltage relationship curve of the Ca2+ current. Anandamide
(100 nM) shifted the steady-state inactivation curve to the left and the recovery
curve to the right (Li, et al., 2009). Blockade of CB1 receptors with AM251, but
not CB2 receptors with AM630, eliminated the effect of AEA on L-type VGCCs.
These data suggest that AEA suppresses L-type VGCCs in cardiac myocytes
through the activation of CB1 receptors (Li, et al., 2009).
The above mentioned studies have indicated that cannabinoids inhibit Ltype Ca2+ channels by the activation of CB1 receptors. However, the CB1 receptorindependent modulation of L-type Ca2+ channels by cannabinoids has also been
reported. In 1988, Janis et al., isolated a lipid fraction from bovine brain and
showed that AEA inhibits the specific [3H] nitrendipine binding to L-type Ca2+
channels in rat cardiac membranes, and it blocks Ca2+ currents in GH3 pituitary
cells (Janis, et al., 1988). Further studies in cortical membranes have also
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identified AEA as an endogenous modulator of L-type Ca2+ channels (Johnson, et
al., 1993).
T-tubules of the skeletal muscles are known to be the richest source of Ltype VGCCs. In T-tubule membrane vesicles from rabbit skeletal muscle fibers,
AEA inhibited the binding of dihydropyridine (DHP) ([3H]PN200-110),
phenylalkylamine ([3H]D888), and 1,5-benzothiazapine ([3H]diltiazem) class of
Ca2+ channel antagonists with IC50 values of 4 µM, 8 µM and 29 µM, respectively
(Shimasue, et al., 1996). In addition, functional studies in T-tubule membranes
indicated that AEA (1-10 µM) and metAEA can inhibit the depolarizationinduced
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Ca2+ fluxes mediated by the activation of L-type Ca2+ channels in a

manner that was insensitive to SR141716A or PTX (Oz, et al., 2000). Further
studies on T-tubule membranes showed that not only AEA, but also 2-AG (1-10
µM), inhibited 45Ca2+ fluxes and displaced the specific binding of DHP (Oz, et al.,
2004a). However, direct effects of these endocannabinoids on L-type Ca2+
channels were not mimicked by the major psychoactive cannabinoid compound of
marijuana, THC, and synthetic CB1 receptor agonists CP55,940 and WIN55,2122.
In adult rat ventricular myocytes, the effect of AA, the metabolic product
of AEA hydrolysis, on L-type Ca2+ channels was also studied (Liu, 2007). It was
found that the exposure to AA directly alters the voltage dependence of gating
properties of L-type Ca2+ channels, and thereby, reduces L-type Ca2+ current,
which accounts for AA inhibition of contraction and Ca2+ transient in rat
ventricular myocytes (Liu, 2007). In a more recent study, it was found that the
synthetic cannabinoid A-955840 inhibits the function of L-type Ca2+ channels in
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rabbit heart in a manner that is not sensitive to CB1 and CB2 antagonists (Su, et
al., 2011).
1.2.6 Role of endocannabinoids in the cardiovascular system
The cardiovascular effects of cannabinoid compounds have been
recognized for several decades (Randall, et al., 2002; Pacher, et al., 2005a). In
humans, the acute effect of smoking Cannabis usually manifests as an increase in
heart rate with no significant change in blood pressure (Kanakis, et al., 1976).
However, chronic use of marijuana in man, as well as, both acute and prolonged
administration of THC to experimental animals, have been shown to cause long
lasting decrease in blood pressure and heart rate (Benowitz and Jones, 1975).
Because of the well-known effects of cannabinoids on the central nervous system,
early research on their cardiovascular effects concentrated on the ability of these
compounds to inhibit sympathetic tone as their mechanism of action (Vollmer, et
al., 1974).
Since the discovery of the endocannabinoid system, regulation of various
cardiovascular functions by these molecules has been studied extensively (Pacher,
et al., 2005a; Pacher and Kunos, 2013). In both in vitro and in vivo studies,
endocannabinoids have been shown to exert complex cardiovascular effects, both
mediated by receptor-dependent and independent mechanisms. In experimental
animals and humans (depending on the route of administration, duration and
dose), the cardiovascular effects of endocannabinoids may include CB1-mediated
bradycardia/tachycardia,

hypotension,

and

depressed

cardiac

contractility

(Malinowska, et al., 2012). Mechanisms of these effects involve modulation of
autonomic outflow through sites of action at presynaptic autonomic nerve
terminals and in the central nervous system, as well as direct effects on
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myocardium and the vasculature (Pacher, et al., 2005a). Despite evidences on the
presence of CB2 receptors in the myocardium (Mukhopadhyay, et al., 2007;
Bouchard, et al., 2003; Montecucco, et al., 2009) and a few recent studies
implicating this receptor in myocardial protection (Bouchard, et al., 2003;
Montecucco, et al., 2009), its role in cardiomyocytes remains elusive. Although
the endocannabinoid system appears to play a limited role in cardiovascular
regulation under normal physiological conditions, it may become overactivated
and play important protective and/or detrimental roles in various disease
conditions (Mukhopadhyay, et al., 2008). The various cardiovascular effects of the
endocannabinoid system are described in the following sections.
1.2.6.1 Cardiovascular effects of endocannabinoids in vivo
Systemic administration of cannabinoids in anesthetized rats and mice
causes hypotension and bradycardia by peripheral inhibition of sympathetic
outflow and increased vagal activity, respectively (Pacher, et al., 2005a).
Anandamide was found to elicit a triphasic blood pressure response with
bradycardia (Figure 1.9) (Varga, et al., 1995; Varga, et al., 1996; Lake, et al.,
1997a; Malinowska, et al., 2012) similar to that reported earlier for THC
(Siqueira, et al., 1979). The initial phase of the response consisted of bradycardia
(with brief secondary hypotension) that lasted for a few seconds only, and was
believed to be vagally mediated, as it was abolished by atropine treatment and
vagotomy. This vagal component was followed by a brief pressor response which
persisted in the presence of α-adrenergic blockade, and also in rats in which
sympathetic tone was abolished by pithing, and was thus not sympathetically
mediated (Varga, et al., 1995).
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Figure 1.9 Typical traces showing the influence of AEA on cardiovascular
parameters in anaesthetized rat. Adapted from Malinowska et al., 2012.
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The pressor component, which constitutes the second phase, was also
unaffected by CB1 receptor antagonists and it persisted in CB1 knockout mice
(Jarai, et al., 1999; Pacher, et al., 2004), indicating the lack of involvement of CB1
receptors. The exact mechanism of this vasoconstrictive response is not well
understood, however, direct action on the vascular smooth muscle has been
proposed (Jarai, et al., 1999). Although the central involvement in the pressor
response was ruled out, centrally administrated cannabinoids can increase the
activity of sympathoexcitatory neurons in the cardiovascular regulatory centers
(Niederhoffer and Szabo, 1999). Therefore, the potential exists that cannabinoids
may increase blood pressure via actions on the central nervous system. Currently
known mechanisms of cannabinoid receptor signaling would suggest that they
principally act via inhibition of neurotransmitter release, suggesting that the
central sympathoexcitatory effects of cannabinoids may be mediated by
disinhibition of inhibitory neurons.
The third phase of AEA effect was hypotension associated with moderate
bradycardia that lasted for 2-10 minutes (Varga, et al., 1995; Varga, et al., 1996;
Lake, et al., 1997a). Interestingly, the third phase was absent in conscious
normotensive rats (Stein, et al., 1996; Lake, et al., 1997a) but present and more
prolonged in conscious, spontaneously hypertensive rats (Lake, et al., 1997b;
Batkai, et al., 2004b). Since sympathetic tone is known to be low in conscious
undisturbed normotensive rats (Carruba, et al., 1987), these observations appear to
be compatible with a sympatho-inhibitory mechanism, underlying AEA-induced
hypotension and bradycardia. The reduction of the sympathetic tone by AEA is
also compatible with early findings with THC, where experimental manipulations
to decrease sympathetic tone resulted in a parallel decrease in the depressor
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response to THC (Vollmer, et al., 1974). Likewise, AEA was unable to reduce
blood pressure in anesthetized rats after cervical transection of the spinal cord or
after blockade of α-adrenoreceptor (Varga, et al., 1995). The finding that metAEA
causes similar but more prolonged hypotension and bradycardia, eliminates the
possibility that the effects of AEA are mediated indirectly by a metabolite (Kunos,
et al., 2000).
Several lines of evidence implicate CB1 receptors in AEA-induced
hypotension and bradycardia. For example, these effects are effectively inhibited
by the selective CB1 receptor antagonist SR141716A (Lake, et al., 1997a; Varga,
et al., 1995). This finding was supported by the total absence of cannabinoidinduced hypotension and bradycardia in CB1 receptor-knockout mice (Ledent, et
al., 1999). Interestingly, in a study carried out by Jerai et al., it was found that
AEA-induced mesenteric vasodilation persisted in mice deficient in CB1 receptors
or in both CB1 and CB2 receptors, suggesting a vasodilatory effect through a site
distinct from CB1 or CB2 receptors (Jarai, et al., 1999). Further evidence for the
involvement of CB1 receptors is that the rank order of the hypotensive and
bradycardiac potency of a series of cannabinoid analogs, including AEA, is
identical to the rank order of potency of the same substances for binding to the
CB1 receptors in rat brain (Lake, et al., 1997a).
Studies have shown that stimulation of presynaptic CB1 receptors inhibits
norepinephrine release on peripheral sympathetic nerves, both in vitro (Ishac, et
al., 1996; Vizi, et al., 2001) and in vivo (Varga, et al., 1996; Malinowska, et al.,
1997), which has a major impact on blood pressure regulation. A recent study
showed that the use of AM3506 (a FAAH inhibitor) in rodents revealed that the
antihypertensive effects of endogenously elevated AEA levels are mediated via
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activation of CB1 receptors in the central nervous system, and a reduction in
sympathetic tone (Godlewski, et al., 2010). Wagner et al., showed that
cannabinoids are potent coronary and cerebral vasodilator agents in the rats in vivo
(Wagner, et al., 2001b). In the same study, the synthetic cannabinoid HU-210 (as
a full agonist for CB1 receptors ) and AEA (as a partial agonist for CB1 receptors),
differed in their effects on cardiac output and systemic vascular resistance
(Wagner, et al., 2001b). Previous studies have also demonstrated that AEA caused
SR141716A-sensitive coronary vasorelaxation in isolated perfused rat hearts
(Randall and Kendall, 1997; Fulton and Quilley, 1998), implicating the
involvement of cannabinoid receptors.
An in vivo study by Ellis et al. demonstrated that AEA causes
cerebrovascular relaxation in the rat that was sensitive to indomethacin
application, indicating that the effect was likely mediated by stimulating the
release and metabolism of endogenous AA (Ellis, et al., 1995).
1.2.6.2 Cardiovascular effects of endocannabinoids in vitro
The vasorelaxant effects of AEA are complex and appear to involve
multiple cellular and molecular mechanisms. Anandamide has been shown to act
via the release of endothelium-derived NO in a range of human blood vessels and
the right atrium (Bilfinger, et al., 1998). Vasorelaxant effects were also seen in the
rat isolated mesenteric (Randall, et al., 1996; Randall, et al., 1997; Plane, et al.,
1997) and coronary vasculature (Randall and Kendall, 1997). However, in both
preparations, AEA-induced relaxation was insensitive to cyclooxygenase
inhibitors, endothelial denudation and inhibition of NO synthesis.
Further studies on the mechanism of AEA-induced vasorelaxant effect
suggest that K+ channels are also involved in their actions. For example, the
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endothelium-independent relaxations by AEA in the mesentery (Randall, et al.,
1996; White and Hiley, 1997) were blocked by raising extracellular K+,
suggesting that AEA-induced responses are mediated by the activation of K+
channels (Randall, et al., 1996; Plane, et al., 1997; White and Hiley, 1997; White
and Hiley, 1998). Furthermore, relaxation to AEA was also sensitive to K+
channel blockade with tetraethylammonium (TEA) (Randall, et al., 1997). In line
with these findings, AEA was found to inhibit delayed rectifier K + channels in rat
aortic and hepatic arterial myocytes (Zygmunt, et al., 1997; Van, I and Vanheel,
2000). The effect of endocannabinoids on Ca2+-activated K+ channels has been
equivocal. Whereas several studies in rat mesenteric arteries suggested a role for
the large conductance Ca2+-activated K+ (BKCa) channels (Plane, et al., 1997;
Ishioka and Bukoski, 1999), others did not (White and Hiley, 1997; Ishioka and
Bukoski, 1999; Fulton and Quilley, 1998). In addition to K+ channels, Ca2+
channels have also been shown to be modulated by endocannabinoids. For
example, AEA-induced relaxation has been attributed to the inhibition of L-type
VGCCs in cat cerebral arterioles (Gebremedhin, et al., 1999). However, another
study has suggested that inhibition of Ca2+ mobilization mediates AEA effect in
rat hepatic arteries (Zygmunt, et al., 1997).
Interestingly, the relaxant effect of AEA shows a significant tissue
selectivity as it does not relax certain blood vessels such as rat carotid arteries
(Holland, et al., 1999) and the rat aorta (Herradon, et al., 2007). However, AEA
does relax rat hepatic and guinea pig basilar arteries (Zygmunt, et al., 1999) and
the bovine coronary artery. Therefore, it is possible that there are regional and
species differences in the actions of endocannabinoids.
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In several studies in rat coronary, mesenteric, renal and rabbit mesenteric
arteries, the vasorelaxant effects of AEA were antagonized by SR141716A,
suggesting the involvement of CB1 receptors (Randall, et al., 1996; Deutsch, et al.,
1997; White, et al., 2001; Fulton and Quilley, 1998; Chaytor, et al., 1999). In
contrast, the relaxant effect of AEA in other studies in rat mesenteric and bovine
coronary arteries was insensitive to SR141716A (Plane, et al., 1997; Pratt, et al.,
1998; Zygmunt, et al., 1999). In a study done in rat mesenteric and hepatic
arteries, and in guinea pig basilary artery, it was reported that AEA-induced
relaxation was unrelated to either endothelium or cannabinoid receptor, but
attributable to activation of TRPV1 receptors located on the perivascular sensory
nerves causing the release of the vasodilatory peptide calcitonin gene-related
peptide (CGRP) (Zygmunt, et al., 1999). Similarly, involvement of TRPV1
receptors in the mesenteric vasodilator action of metAEA has also been suggested
(Ralevic, et al., 2000). In this study, CGRP receptor antagonist and capsazepine
inhibited the response to metAEA supporting the involvement of TRPV1 channels
in the vasorelaxant action of AEA (Ralevic, et al., 2000).
In contrast to the increasing knowledge on the vascular effects of
endocannabinoids, little is known about the effects of endocannabinoids on
cardiac muscle. In earlier studies, the cardiodepresssant effects of HU-210 and
AEA, have been shown in isolated electrically stimulated human artrial
appendages (Bonz, et al., 2003) and in isolated Langendorff rat hearts (Ford, et al.,
2002). These in vitro studies are in agreement with earlier in vivo studies,
indicating that AEA reduces both cardiac contractility and total peripheral
resistance (Batkai, et al., 2004b). In isolated section of human right atrium (atrial
appendage), AEA, metAEA and HU-210 dose-dependently decreased the
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contractile performance. The negative inotropic effect was blocked by AM251 but
not AM630. Indomethacin did not prevent the depression of contractility by AEA,
and metAEA displayed the same effects as AEA (Bonz, et al., 2003).
Furthermore, AEA continued to decrease the contractile performance in the
presence of L-NAME, an inhibitor of nitric oxide synthase (NOS) (Bonz, et al.,
2003). These findings suggest that the effects of AEA on contractile function are
not mediated by CB2 receptor activation, NO, or prostanoid release. Consistent
with these findings, HU-210 decreased left ventricular pressure in isolated
perfused rat heart (Maslov, et al., 2004; Krylatov, et al., 2005), and decreased
myocardial contractility without a major effect on the total peripheral resistance
(Pacher, et al., 2005a).
In an electrophysiological study in rat cardiac papillary muscle, AEA, at
low concentrations (0.1-1µM), decreased the AP duration in a concentrationdependent manner and suppressed the amplitudes of cardiac APs (Li, et al., 2009).
Furthermore, AEA inhibited L-type Ca2+ currents in ventricular myocytes.
Blockade of CB1 receptors with AM251, but not CB2 receptors with AM630,
eliminated the effect of AEA suggesting that the effects of AEA are mediated
through CB1 receptors (Li, et al., 2009). In another study in rat heart, Ford et al.,
showed that AEA induces negative inotropic responses in isolated Langendorff
heart (Ford, et al., 2002). Interestingly, the cannabinoid anatagonists SR141716A,
AM281 and SR144528 significantly blocked the negative inotropic responses to
AEA that were not significantly affected by AM251, AM630 and capsazepine,
which led the authors to propose a novel site distinct from the classic CB 1 and CB2
receptors (Ford, et al., 2002).
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In addition to cannabinoid receptor-dependent effects in the heart,
endocannabinoids can also interact directly with several classes of cardiac
voltage-gated ion channels in a cannabinoid receptor-independent manner. For
example, AEA is a potent blocker of potassium channel Kv1.5 which is highly
expressed in human atria, and contributes to AP repolarization of human atrial
myocytes (Barana, et al., 2010; Amoros, et al., 2010; Moreno-Galindo, et al.,
2010). Concurrent with these results, AEA has been also shown to block cardiac
Kv4.3 potassium channel in a receptor-independent manner (Amoros et al., 2010).
Overall, these earlier studies suggest that cannabinoids have negative inotropic
action on cardiac muscle. However, the role of cannabinoid receptors in mediating
this effect is currently not clear.
1.2.6.3 Endocannabinoid system in cardiovascular disease
Despite the presence of cannabinoid receptors, endocannabinoids and their
metabolizing enzymes, the molecular mechanisms and physiological significance
of the endocannabinoid system in the cardiovascular system under normal and
pathological conditions are not fully understood. It has been widely accepted that
the endocannabinoid system plays a limited role in cardiovascular regulation
under normal physiological conditions, which is supported by the normal blood
pressure, myocardial contractility and baroreflex sensitivity of cannabinoid
receptor, or FAAH knockout mice (Pacher, et al., 2005b; Pacher, et al., 2006).
Baseline cardiovascular parameters, systolic and diastolic functions, and
baroreflex sensitivity were found to be similar in FAAH−/− and FAAH+/+ mice.
This suggests that, under normal physiological conditions, the absence of FAAH
does not lead to the appearance of an endocannabinergic tone on the
cardiovascular system (Pacher, et al., 2005b). In addition, in normotensive mice, it
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was found that baseline blood pressure is similar in CB1-knockout mice and their
wild-type littermates (Ledent, et al., 1999). However, in many pathological
conditions such as heart failure, the endocannabinoid system may become
overactivated and may contribute to hypotension/cardiodepression through
cardiovascular cannabinoid receptors (Manitiu, 2013).
The levels of AEA, but not 2-AG, are elevated in the hearts of FAAH-/mice (Pacher, et al., 2005b). Interestingly, these mice also show decreased
deterioration of cardiac function with age relative to their FAAH+/+ littermates
(Batkai, et al., 2007), which may be due to the enhancement of the effects of
endogenous AEA. The finding of measurable levels of AEA in mouse heart
contrasts with an earlier report that AEA was undetectable in lipid extracts of
normal rat heart, although 2-AG was present (Schmid, et al., 2000). Nevertheless,
it seems that both synthetic and metabolic pathways for endocannabinoids are
present in the mammalian heart. However, the capacity for producing NAPE
precursor appears to be low in several species, including humans (Moesgaard, et
al., 2002), and with the exception of mice, the evidence for AEA synthesis and
activity is generally circumstantial. On the other hand, alterations in
endocannabinoid system tone has been suggested to be associated with various
pathological states as a result of the altered expression of cannabinoid receptors,
endocannabinoid metabolizing enzymes and synthetic pathways, in a tissue
specific and time-dependent manner (Pacher and Kunos, 2013).
Earlier studies in cardiac muscle have shown that a considerable elevation
in NAEs content can occur under hypoxic conditions when extensive membrane
degradation occurs during myocardial infarction (Schmid, et al., 1996; Epps, et
al., 1979; Epps, et al., 1982). In fact, accumulation of NAEs during pathological
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conditions was first observed in experimental myocardial infarction induced by
ligation of coronary arteries in canine heart (Epps, et al., 1982; Epps, et al., 1979).
In cultured human coronary artery endothelial cells (Rajesh, et al., 2010)
and cardiomyocytes (Mukhopadhyay, et al., 2010), CB1 activation has been shown
to promote stress signaling, cell death, and decreased contractility (Pacher, et al.,
2008; Montecucco and Di Marzo, 2012). Furthermore, in several pathological
conditions (e.g. shock, heart failure, cardiomyopathies and advanced liver
cirrhosis), the endocannabinoid system may become activated to promote
hypotension and cardiodepression through cardiovascular CB1 receptors (Pacher,
et al., 2006; Pacher, et al., 2008). In rat models of acute and chronic myocardial
infarction, studies with CB1 agonists/antagonists yielded conflicting results. For
example, the findings by Wagner et al. indicated that the activation of CB1
receptors contributes to severe hypotension after experimental myocardial
infarction in rats. In this study, the selective CB1 antagonist SR141716A
prevented

post-myocardial

infarction hypotension,

but

aggravated

early

endothelial dysfunction and worsened mortality (Wagner, et al., 2001a). In a
subsequent study, the authors reported a deleterious effect of CB1 antagonism with
AM251 on cardiac function in a chronic myocardial infarction model. On the
other hand, treatment with the synthetic agonist HU-210 prevented hypotension
and endothelial dysfunction in aortic rings isolated from treated rats (Wagner, et
al., 2003). A possible explanation of the conflicting results in these two studies
might be the involvement of non-CB1 receptor mediated effects.
More recent evidence suggested a cardioprotective role of CB1
antagonism. The role of the endocannabinoid system was explored in a model of
doxorubicin (DOX)-induced heart failure (Mukhopadhyay, et al., 2010).
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Following DOX administration, the tissue AEA content, but not CB1/CB2 receptor
expression, was elevated in the myocardium and also in cardiomyocytes exposed
to DOX in vitro, suggesting activation of the endocannabinoid system.
Pretreatment of mice with CB1 antagonists, SR141716A and AM281, not only
improved DOX-induced cardiac dysfunction, but also attenuated the DOXinduced cell death in vivo and in vitro. These observations suggest that the
cytoprotective role of CB1 antagonists in cardiac pathologies may extend beyond
the hemodynamic effects.
Other studies have also supported the role of the endocannabinoid system
in cellular metabolism and viability. For example, AEA was shown to limit the
damage induced by ischemia-reperfusion in rat isolated hearts (Underdown, et al.,
2005; Lepicier, et al., 2007). Similarly, AEA has been shown to protect the heart
from adrenaline-induced arrhythmias (Ugdyzhekova, et al., 2001) and arrhythmias
induced by ischemia-reperfusion through the stimulation of CB2 receptors
(Krylatov, et al., 2002). Furthermore, using potent CB2 receptor agonists and
knockout mice, it has been demonstrated that CB2 receptor activation has a
protective effect against myocardial ischemic-reperfusion injury (Hajrasouliha, et
al., 2008). Another study in isolated rat heart provided direct evidence of the
potential cardioprotective role of endocannabinoids and AEA-related mediator
signaling in ischemia-reperfusion injury was investigated (Lepicier, et al., 2003).
Interestingly, it was shown that perfusion with PEA and 2-AG, but not AEA,
decreased myocardial damage in isolated rat hearts. In addition, infarct size was
limited by either a selective CB1 agonist (arachidonoyl-2chloroethylamide;
ACEA) or a selective CB2 agonist (JWH015). However, PEA is supposedly
inactive at CB1 and CB2 receptors, a fact supported by the finding that PEA was
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devoid of activity when administered to rat isolated heart (Ford, et al., 2002). In
contrast, AEA causes negative inotropy and coronary vasodilatation in rat isolated
hearts (Ford, et al., 2002). It is therefore interesting that AEA failed to reduce
myocardial infarction injury while PEA and 2-AG were effective. In a subsequent
study in isolated rat heart, however, AEA perfusion reduced the infarct size,
which was blocked by either CB1 or CB2 antagonism, using SR141716A or
SR144528, respectively. However, using Arachidonoyl cyclopropylamide
(ACPA; CB1 agonist) and JWH-133 (CB2 agonist) could not mimic the effect of
AEA, suggesting the involvement of a novel cannabinoid site of action
(Underdown, et al., 2005).
Activation of CB2 receptors in inflammatory cells and endothelium has
been suggested to attenuate TNF-α-induced endothelial inflammatory response,
chemotaxis, and adhesion of inflammatory cells to the activated endothelium.
Subsequent release of various proinflammatory mediators (key processes involved
in the initiation and progression of atherosclerosis, restenosis and reperfusion
injury) (Mach, et al., 2008; Pacher and Hasko, 2008), and smooth muscle
proliferation have also been proposed to be decreased after the activation of CB2
receptors (Rajesh, et al., 2007). However, the role of myocardial CB2 receptors
during ischemia-reperfusion and other cardiovascular pathologies is currently not
well established.
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The main objectives of the current study are:
1. To test the effects of AEA on contractility and Ca2+ signaling in rat
ventricular myocytes.
2. To test the effects of AEA on the characteristics of cardiac action
potential.
3. To study the effects of AEA on cardiac voltage-activated inward Na+ (INa)
and Ca2+ (IL,Ca) currents, which are the major inward currents shaping the
action potential in ventricular myocyte.
4. To study the effects of AEA on cardiac sodium-calcium exchanger (NCX).
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2. MATERIALS AND METHODS
2.1 Experimental animals
The work was performed with approval of the Animal Research Ethics
Committee of the College of Medicine and Health Sciences (Al Ain, UAE). The
original stock of Wistar rats were purchased from Harlan Laboratories (Oxon,
England). Animals were bred at our own Animal Facility from the original stock.
The animals were housed in polypropylene cages (43 x 22.5 x 20.5 cm; six rats/
cage) in climate and access controlled rooms (22-24 °C; 50 % humidity). The day/
night cycle was 12 h/12h. Food and water were provided ad libitum. The food was
standard maintenance diet for rats purchased from Emirates Feed Factory (Abu
Dhabi, UAE).
2.2 Ventricular myocyte isolation
Ventricular myocytes were isolated from adult male Wistar rats (264 ± 19
g) according to previously described technique (Howarth, et al., 2002). The
animals were euthanized using a guillotine and hearts were removed rapidly and
immersed in cold perfusate to limit any ischemic injury during the period between
excision and the restoration of vascular perfusion. Having cleared extraneous
tissue, the aorta was carefully eased over the tip of the cannula and mounted for
retrograde perfusion according to Langendorff method. The Langendorff
apparatus (Figure 2.1) employed a roller (peristaltic) pump (Minipuls3, Gilson,
France) which was set to deliver isolation solution at a constant flow rate (8
ml/minute/g weight of tissue) and at 36-37 ˚C with a solution containing (mM):
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Figure 2.1 Langendorff apparatus: Arrangement of the system (upper panel),
heat exchanger and heart warming jacket (lower left panel) and cannulated heart
(lower right panel).
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130 NaCl, 5.4 KCl, 1.4 MgCl2, 0.75 CaCl2, 0.4 NaH2PO4, 5 HEPES, 10 glucose,
20 taurine, and 10 creatine set to pH 7.3 with NaOH.
Once the heart contraction had stabilized, perfusion was continued for 4
minutes with Ca2+-free isolation solution containing 0.1 mM EGTA, and then for
6 minutes with cell isolation solution containing 0.05 mM Ca2+, 0.75 mg/ml
collagenase (type 1; Worthington Biochemical Corp, USA) and 0.075 mg/ml
protease (type X1 V; Sigma, Germany). Ventricles were then excised from the
heart, minced and gently shaken in a collagenase-containing isolation solution
supplemented with 1 % BSA for 4 minutes at 36-37 °C. The suspension was then
filtered through a nylon mesh (pores of 300 μm). Tissue remaining in the nylon
mesh was re-suspended in collagenase-containing isolation solution supplemented
with 1 % BSA and shaken for 4 minutes at 36-37 °C. The filtrate suspension of
cells was centrifuged at 400 rpm for 1 minute. Subsequently, the supernatant was
removed and the cell pellet was re-suspended in isolation solution containing 0.75
mM Ca2+. This process was repeated four times. Ventricular myocytes were
collected from second, third and fourth shakes and stored at 4 °C. Experiments
were performed in ventricular myocytes that displayed rod-shaped morphology
and regular striations (Figure 2.2).
2.3 Measurement of ventricular myocyte shortening
Shortening of myocytes was recorded using a video edge detection system
(VED-114, Crystal Biotech, USA) (Figure 2.3; for the arrangement of the
recording system used for video edge detection experiments). This system is used
for measuring the length or width of cells or small tissues in real-time. The video
edge detection system was composed of a high-speed video camera (Myotrac,
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Crystal Biotech, UT, USA), an analog dual-edge detector (VED-114, Crystal
Biotech, USA), a data logging device (CED-1401+, Cambridge Electronic Design,
Cambridge, Cambridge, UK), a PC and a monitor. The system is able to record up
to 240 length measurements per second.

Figure 2.2 Micrographs of ventricular cells: The upper panel shows a collection
of viable (rod-shaped) and nonviable (round-shaped) ventricular myocytes. The
lower panel shows a single freshly isolated ventricular myocyte. Myocytes were
typically 80-120 μm in length.
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Figure 2.3 The recording system used for video edge detection and Ca 2+
imaging experiments: The system includes an anti-vibration table (A), a Faraday
cage (B), an inverted microscope (C), a cell superfusion system (D) with a
temperature control system (E), a video edge motion detector (F), a
microfluorescence photometry system (G) and an electrical stimulator (H).
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Ventricular myocytes were first allowed to settle on the glass bottom of a
Perspex chamber mounted on the stage of an inverted microscope (Axiovert 35,
Zeiss, Germany). Cells were then electrically stimulated at 1 Hz to produce
contraction by means of two platinum electrodes positioned around the
circumference of the chamber and connected to an electrical stimulator (SD-5,
Grass Instruments, USA). Using a microscope equipped with a high-speed
camera, the cell is positioned so that the axis of contraction runs from left to right
on the video screen. The cursors were positioned over the edges of the cell (Figure
2.4). The raster line was adjusted to move the cursors upwards or downwards. The
edge detector triggers on the first large white/black or black/white transition
within the left cursor and the last white/black or black/white transition within the
right cursor. Switches set the desired transition type (black/white or white/black)
and the threshold for each cursor. Under these conditions, slightly defocusing the
cell image can enhance the edge contrast. A white dot within each cursor shows
the edge as detected by the system. An analog voltage output proportional to the
distance between the two edges is conveyed to the data logging device
(CED1401+, Cambridge Electronic Design, Cambridge, UK), and to the
computer. Data were acquired and analyzed with Signal Averager software v 6.37
(Cambridge Electronic Design, UK).
Myocytes were superfused (3–5 ml/min) with normal Tyrode (NT)
containing (in mM): 140 NaCl, 5 KCl, 1 MgCl2,10 glucose, 5 HEPES and 1.8
CaCl2 (pH 7.4). Inflow of superfusate to the chamber was controlled by two
micropumps (P07002-39/P07002-33, Cole-Parmer, USA). Outflow and the level
of fluid in the chamber was controlled by a glass tube dipping into the chamber
and connected to a waste bottle which in turn was connected to a service vacuum
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Figure 2.4 Video edge motion detection: The upper panel shows the video edge
motion detector. The lower panel shows a ventricular myocyte with video edge
cursors positioned across the edges of the cell.
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line. The temperature of the chamber solution was regulated by a temperature
controller (TC-20, NPI, Germany), which comprised a heating coil wound around
the inflow line, a thermistor located in the chamber and the control system.
Resting cell length (RCL), time to peak (TPK) shortening, time from peak to half
relaxation (THALF) and amplitude of shortening (expressed as a % of resting cell
length) were measured under these conditions.
2.4 Western immunoblot assay
Ventricles were obtained from normal Wistar rats as described earlier in
section 2.2. In the first step, tissue samples were flash-frozen in liquid nitrogen
and stored at -80 °C for later use. After thawing, tissue extracts were prepared by
homogenization on ice with RIPA buffer (Pierce Biotechnology, IL, USA)
supplemented with protease inhibitors (Roche, GmbH, IN, USA). Later, the
extracts were clarified to remove the cellular debris by centrifugation at 13000
r.p.m. for 15 minutes at 4 ºC. Protein content in the extracts was determined using
the Lowry assay (BioRad). A measure of 50 µg protein was resolved in 12 %
SDS-PAGE and was transferred onto nitrocellulose membranes (GE Healthcare,
UK). Blocking was performed for 2 hours at room temperature with 5 % non-fat
skimmed milk powder prepared in phosphate buffer solution (PBS) containing 0.1
% Tween 20 (Sigma, CA, USA). After washing with phosphate-buffered saline
0.1 % Tween 20 (PBST), the membranes were probed with either rabbit
polyclonal CB1 (Cayman Chemicals, 1: 1000 dilution) or with an antibody raised
against the last 15 residues of rat CB1 or CB2 antibody (Cayman Chemicals, 1:
1000 dilution) overnight at 4 ºC. After subsequent washing with PBST, the
secondary antibody (goat anti- rabbit) coupled with HRP (horseradish peroxidase)
(GE Biosciences, UK) was added and the blots were incubated at room
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temperature for 1 hour. Later, the membranes were developed using a
chemiluminescence detection kit (Super Signal-West Pico Substrate, Pierce). To
confirm uniform loading, the membranes were stripped and re-probed with β-actin
(Chemicon, CA, USA).
2.5 Measurement of intracellular Ca 2+ concentration
In order to measure intracellular Ca2+ concentration, ventricular myocytes
were loaded with the fluorescent indicator fura-2 AM (F-1221, Oregon, Molecular
Probes, USA) (Howarth, et al., 2002). Fura-2, a polyamino carboxylic acid, is an
ultra violet light-excitable ratiometric Ca2+ indicator. In its salt form, fura-2 can be
introduced into the cell by microinjection. As an acetoxymethyl (AM) ester, it can
passively diffuse across cell membranes. Once inside the cell, the esters are
cleaved by intracellular esterases to yield cell-impermeable fluorescent indicators.
Upon binding to Ca2+, fura-2 AM exhibits an absorption shift that can be observed
by scanning the excitation spectrum at wavelengths between 300 nm and 400 nm,
while monitoring the fluorescence emission at wavelength ~ 510 nm.
The fluorescence photometry system was used to generate excitation light
and collect emissions (Cairn Research, Kent, UK). A monochromator, comprising
the light source (75 W Xenon arc lamp), rapid galvanometer diffraction grating
and automated exit slit generated excitation light of required wavelength,
bandwidth and intensity. In the case of fura-2 AM, the excitation light alternated
rapidly between 340 and 380 nm. The light was transmitted from the source via a
liquid light guide and various mirrors and a FLUAR 40x/1.30 (ultraviolet
transmitting) oil-immersed objective to the fura-2 AM loaded cell. A 400 nm long
pass dichroic filter reflected light < 400 nm to the cell. Light emitted from the cell
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was directed through the objective and through a 600 nm long pass dichroic filter
which transmitted red bright field light > 600 nm to a high-speed video camera
(Myotrac, Crystal Biotech, UT, USA) so that the cell could be visualized on a
monitor. Finally, fluorescence light < 600 nm was directed via a 480 nm longpass emission filter to a bi-alkali photomultiplier tube (C151, Cairn Research,
Kent, UK) and thence, as a high voltage signal, to the control system (C208, Cairn
Research, Kent, UK). The control system collected 340 and 380 nm signals and
generated a ratio (340/380 nm) signal. These signals were conveyed via a data
logging device (CED-1401+, Cambridge Electronic Design, Cambridge, UK) to
the computer for processing and for display on the computer monitor. The
340/380 fura-2 AM ratio provided the index of intracellular Ca2+.
In our experiments, 6.25 µl of a 1 mM stock solution of fura-2 AM
(dissolved in DMSO) was added to 2.5 ml of cells to give a final fura-2 AM
concentration of 2.5 µM. Myocytes were shaken gently for 10 minutes at room
temperature. After loading, myocytes were centrifuged, washed with normal
Tyrode to remove extracellular fura-2 AM and then left for 30 minutes to ensure
complete hydrolysis of the intracellular ester. In order to measure intracellular
Ca2+ concentration, myocytes were alternately illuminated by 340 nm and 380 nm
light using a monochromator (as mentioned earlier) which changed the excitation
light every 2 milliseconds. The resulting fluorescence emitted at 510 nm was
recorded by the photomultiplier tube and the ratio of the emitted fluorescence at
the two excitation wavelengths (340/380 ratio) was calculated to provide an index
of intracellular Ca2+ concentration.
Data were acquired and analyzed with Signal Averager software v 6.37
(Cambridge Electronic Design, UK). Resting fura-2 ratio, TPK Ca2+ transient,
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THALF decay of the Ca2+ transient, and the amplitude of the Ca2+ transient were
measured in electrically stimulated (1 Hz) myocytes.
2.6 Measurement of sarcoplasmic reticulum Ca2+ content
Sarcoplasmic reticulum (SR) Ca2+ release was assessed using previously
described technique (Howarth, et al., 2002; Bassani, et al., 1995). After
establishing steady state Ca2+ transients in electrically stimulated (1 Hz) myocytes
maintained at 35–36 ˚C and loaded with fura-2, stimulation was paused for a
period of 5 seconds. Caffeine (20 mM) was then applied for 10 seconds using a
solution switching device customized for rapid solution exchange. Electrical
stimulation was resumed and the Ca2+ transients were allowed to recover to steady
state levels. SR-releasable Ca2+ was assessed by measuring the area under the
curve of the caffeine-evoked Ca2+ transient. Fractional release of SR Ca2+ was
assessed by comparing the amplitude of the electrically evoked steady state Ca2+
transients with that of the caffeine-evoked Ca2+ transient and refilling of SR was
assessed by measuring the rate of recovery of electrically evoked Ca 2+ transients
following application of caffeine.
2.7 Assessment of myofilament sensitivity to Ca2+
In some cells shortening and fura-2 ratio were recorded simultaneously.
Myofilament sensitivity to Ca2+ was assessed from phase-plane diagrams of fura-2
ratio vs. cell length by measuring the gradient of the fura-2-cell length trajectory
during late relaxation of the twitch contraction (Spurgeon, et al., 1992). The
position of the trajectory reflects the relative myofilament response to Ca 2+ and
hence, can be used as a measure of myofilament sensitivity to Ca 2+.
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2.8 Electrophysiological recording of whole-cell currents (Patch clamp
technique)
2.8.1 Pipettes
The pipettes for recording in ventricular myocytes were fabricated from
filamented BF 150-86-10 borosilicate glass (OD= 1.5 mm, ID= 0.86 mm, Sutter
Instruments Co., CA, USA) using a horizontal puller (Sutter Instruments Co., CA,
USA). In order to get a good contact between the electrode and the cell membrane
without damaging the cell membrane, the electrode tips were fire-polished using a
microforge (Zeiss ID03, Germany). Electrode resistance ranged between 2.0 and
4.0 MΩ as assessed in our standard pipette and extracellular solutions using the
pClamp 10 software.
2.8.2 Seal Penetration
Whole-cell version of the patch clamp technique was used to measure ion
currents (see Figure 2.5; for the arrangement of the patch clamp setup). Cells were
mounted on the stage of an inverted phase-contrast microscope (Nikon diaphot,
Tokyo, Japan). The output signals were filtered at 5 KHz with an 8 pole filter, and
stored on the hard disk of a computer for off-line analysis. The pipette, which had
a small positive internal pressure in order to keep the tip clean, was pushed gently
onto the cell surface by using a three-axis micromanipulator (ACCi UI,
Scientifica, UK). A tight seal (gigaseal) between the membrane and the tip of the
pipette (1-10 GΩ) was obtained by the application of suction through the pipette.
Further suction disrupted the membrane under the tip of the pipette allowing the
pipette solution to dialyze the cell (Figure 2.6). The experiments were carried out
at room temperature (22–24 ºC) in order to ensure a longer survival time of
patched cells and a better time resolution of the membrane currents.
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Figure 2.5 Patch clamp experimental setup: The patch pipette with internal
recoring electrode (A) and reference electrode (B) are connected to the headstage
(C) which is mounted on a micromanipulator (D). Isolated cells are visualized
with an inverted light microscope (E). The microscope, the micromanipulator, and
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headstage are placed on an anti-vibration table (F) to isolate these components
from vibrations that may interfere with gigaseal formation and placed in a Faraday
cage (G) to shield the setup from ambient electrical noise. The flow of the currents
into the pipette can be recorded using a highly sensitive amplifier (H) which is
connected to an analog to digital converter (digitizer) (I), where the signal is
digitized and sent to a computer for data analysis. A computer screen (J) is used
for monitoring experiments and for data display.
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Figure 2.6 Schematic presentation of whole cell configuration of patch clamp
technique.
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The membrane currents of cardiac ventricular myocytes were recorded
using an Axopatch 200B amplifier (Molecular Devices, Downington, PA, USA)
linked to an A/D interface (Digidata 1322; Molecular Devices) connected to an
IBM computer.
Cells that had stable currents from the third to fifth minutes after
penetration of the membrane were used in the majority of our experiments. Drugs
were tested once the whole-cell currents had reached a stable level (usually 10
minutes after obtaining the whole-cell configuration). A series of voltage steps
were applied to determine the current-voltage relationship. Different drugs were
then added directly to the bath solution and the change in the magnitude of current
was monitored continuously. In some cells the bath solution was changed to
assess the recovery after washout of tested compound.
The rate of solution flow to the recording chamber was controlled by two
micropumps (Micropump Inc., WA, USA). Changes of external solutions and
application of drugs were performed using a multi-line perfusion system with a
common outflow connected to recording chamber. Electrophysiological data were
analyzed using pClamp 10.2 (Molecular Devices, Union City, CA) and Origin 7.0
(OriginLab Corp., Northampton, MA) software. The amplitudes of the currents
were normalized to cell membrane capacitance (nA/pF).
2.8.3 Measurement of action potentials
2.8.3.1 Protocol for measuring action potentials
APs were measured using the current clamp mode of the whole-cell patch
clamp technique. After giga seal formation, the membrane was ruptured with
gentle suction to obtain whole cell configuration. The generation of APs was
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evoked by 0.9-1 nA depolarizing current pulses of 4 ms duration applied at a
frequency of 0.2 Hz. During a typical experiment, the following protocol was
employed: first, whole-cell configuration was established and 4 to 5 minutes
dialysis of the myocytes with pipette solution was allowed to ensure the
equilibrium conditions between the pipette solution and intracellular milieu.
Subsequent to achieving stable recordings of baseline electrical activity (Vrest and
AP parameters), myocytes were exposed to the tested drug for 10 to 15 minutes
and subsequently it was washed out.
2.8.3.2 Solutions
Basic extracellular solutions used for electrophysiological recordings
contained (in mM): 144 NaCl, 5.4 KCl, 1.8 CaCl2, 1.2 MgCl2, 1 NaH2PO4, 10
HEPES, 10 glucose, and pH 7.4 (adjusted with NaOH). Recording patch pipettes
were filled with intracellular solution containing (in mM): 10 KCl, 10 KOH, 105
K-aspartate, 15 NaCl, 1 MgCl2, 10 HEPES, 4 Mg-ATP, 5 Sucrose, and рН 7.2
(adjusted with HCl).
2.8.4 Measurement of Na + currents
2.8.4.1 Protocol for measuring Na + currents
For recording of sodium currents (INa), data were elicited from a holding
potential of -80 mV and depolarized with 50 ms pulses to +60 mV in 10 mV
increments every 10 seconds. Steady-state activation (SSA) curves of INa before
and after AEA application were derived by fitting the respective current-voltage
relationship (I-V) with the product of Boltzmann equation which describes
voltage-dependence of SSA. This allowed us to determine if the drug influences
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the parameters of INa SSA, the voltage of half-maximal activation (V1/2) and the
slope factor (k).
The conductance was calculated using the following equation, G = I/(Vm Vrev), where I is the current amplitude, Vm is the test potential and Vrev is the
reversal potential. The corresponding steady-state activation curves were obtained
by normalizing the conductance to the peak conductance. The normalized
conductances (G/Gmax) were then plotted against the test potentials and fitted
with the Boltzmann equation:
G /Gmax=1/ 1+exp[−(Vm−V1/2)/ k]
where V1/2 is the voltage at half-maximal conductance and k is the slope factor.
In order to determine if the drug influences the properties of VGSCs
inactivation, we compared steady-state inactivation (SSI) dependencies of INa in
the absence and presence of tested drug. SSI curves were acquired using a
standard voltage protocol consisting of a prolonged (400 ms) preconditioning
pulse to various Vm in the range of -100 mV to +70 mV which was immediately
followed by the constant INa activating test pulse to Vm= -20 mV. SSI-dependency
was plotted as normalized amplitude of INa at Vm= -20 mV against the value of
conditioning Vm. Current amplitude was normalized to the peak current (I/Imax),
and plotted against each conditioning potential. The steady-state inactivation
curves were fitted with the Boltzmann function,
I /Imax=1/ 1+exp[(Vm−V1/2)/ k]
where V1/2 is the voltage at which half the channels are available for opening, and
k is the slope factor.
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2.8.4.2. Solutions
Extracellular solution for recordings of INa consisted of (in mM): 100
TEACl, 40 NaCl, 10 Glucose, 1 MgCl2, 5 CsCl, 0.1 CaCl2, 1 NiCl2, and 10
HEPES (adjusted to pH 7.3 with CsOH). Intracellular solution contained (in mM)
135 CsCl, 5 NaCl, 10 EGTA, 10 HEPES and 1 MgATP (adjusted to pH 7.25 with
CsOH).
2.8.5 Measurement of L-type Ca2+ currents
2.8.5.1 Protocol for measuring L-type Ca2+ currents
For recording of Ca2+ currents (IL,Ca), data were elicited from a holding
potential of −50 mV to membrane potentials ranging from -70 mV to +70 mV in
10 mV increments for 300 ms. Elimination of contaminating INa during recording
of ICa was achieved by applying voltage step-pulses from relatively depolarized Vh
of -50 mV, which produced steady-state INa inactivation.
The conductance was calculated using the following equation, G = I/(Vm Vrev), where I is the current amplitude, Vm is the test potential and Vrev is the
reversal potential. The corresponding steady-state activation curves were obtained
by normalizing the conductance to the peak conductance. The normalized
conductances (G/Gmax) were then plotted against the test potentials and fitted
with the Boltzmann equation:
G /Gmax=1/ 1+exp[−(Vm−V1/2)/ k]
where V1/2 is the voltage at half-maximal conductance and k is the slope factor.
The steady-state inactivation curves were obtained using a standard
voltage protocol, in which 1 second preconditioning pulses from a holding
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potential of -50 mV were elicited in the voltage range of -70 mV to +70 mV in 10
mV increments which was immediately followed by the constant IL,Ca activating
test pulse to Vm= +10 mV. SSI-dependency was plotted as normalized amplitude
of IL,Ca at Vm= +10 mV against the value of conditioning Vm. Current amplitude
was normalized to the peak current (I/Imax), and plotted against each conditioning
potential. The steady-state inactivation curves were also fitted with the Boltzmann
function,
I /Imax=1/ 1+exp[(Vm−V1/2)/ k]
where V1/2 is the voltage at which half the channels are available for opening, and
k is the slope factor.
2.8.5.2 Solutions
In order to prevent the cells from contracting during patching, they were
first patched in a Ca2+ free solution which consisted of (in mM): 120 NaCl, 1
EGTA, 10 MgCl2, 10 Glucose, 10 HEPES, 1 NaH2PO4 and 5 KCl. Once the whole
cell configuration was obtained, the recoding solution was applied. The whole-cell
bath solution contained (in mM): 95 NaCl, 50 TEACl, 2 MgCl2, 2 CaCl2, 10
HEPES and 10 Glucose (adjusted to pH 7.35 with NaOH). The pipette solution
contained (in mM): 140 CsCl, 10 TEACl, 2 MgCl2, 2 HEPES 1 MgATP and 10
EGTA (adjusted to pH 7.25 with CsOH).
2.8.6 Measurement of Na+/Ca2+ exchanger currents in cardiomyocytes
2.8.6.1 Protocol for measuring Na +/Ca2+ exchanger currents
INCX was recorded using a descending voltage ramp from +100 mV to -100
mV from a holding potential of -40 mV for 2 seconds duration. As described
previously (Hinde, et al., 1999), INCX was measured as current sensitive to nickel
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(Ni2+). Therefore, Ni2+-insensitive components were subtracted from total currents
to isolate INCX.
2.8.6.2 Solutions
The cells were first patched in a Ca2+-free solution as described previously
(section 2.7.5.2). External solution contained (in mM): 150 NaCl, 5 CsCl, 2
CaCl2, 2 MgCl2, 10 HEPES, 10 Glucose (pH=7.4). Nifedipine (10 µM), Oubain
(100 µM), and Niflumic acid (30 µM) were used to block Ca2+, Na+-K+ ATPase,
and Cl- currents, respectively. 10 mM nickel chloride solution was used to block
INCX. K+ currents were minimized by Cs+ substitution for K+ in both pipette and
external solutions. The pipette solution contained (in mM): 120 CsCl, 20 NaCl2,
10 TEACl, 2 MgCl2, 1 CaCl2, 10 HEPES, 1 MgATP and 10 BAPTA (pH= 7.2
with CsOH). The combination of 10 mM BAPTA and 1 mM Ca2+ in the pipette
solution gave a free [Ca2+]i of 20 nM (calculated with the “Maxchelator program”;
WEBMAX v 2.10, Stanford, CA, USA, which was supplied by Dr. D. Bers).
2.9 Biochemical assessment of cell viability and membrane integrity of
ventricular cardiomyocytes
2.9.1 MTT cell viability assay
The effect of AEA on cell viability was measured using MTT assay which
is based on the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyl tetrazolium
(MTT) bromide into formazan crystals by the mitochondrial succinate
dehydrogenase of viable cells. Cells were plated in 96-well plates at a density
10,000 cells/well in a Ca2+-free solution (See section 2.6.4.2 for solution
composition). Cell count was estimated by mixing 20 µl of cells with 180 µl of
trypan blue and counting the number of viable cells using a hemocytometer. Cells
were incubated for 40 minutes with or without tested drug at 37 °C in a 5 % CO2
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humidified atmosphere. 2 μl of Triton X-100 (9 % in water solution) per 100 μl
original volume was used as a positive control to produce cell lysis. After
incubation, 25 μl of MTT (5 mg/ml) were added to each well and the plates were
incubated for a further 3 h at 37 °C. Then the plates were centrifuged at 1500 rpm
for 5 minutes and the solutions were carefully decanted from all the wells. The
formazan crystals that formed were then solubilized in a 200 μl of DMSO. The
colored solution was quantified at 570 nm using Perkin Elmer Victor-3
Spectrophotometer. The cytotoxicity was expressed as percentage over control.
2.9.2 Homogenous membrane integrity assay
Membrane integrity was assessed using the CytoTox-ONE Assay
(Promega, Madison, USA). This is a rapid, fluorescent measure of the release of
lactate dehydrogenase (LDH) from cells with a damaged cell membrane. The test
is based on the conversion of resazurin into resorufin as shown in figure 2.7.
Generation of the fluorescent resorufin product is proportional to the amount of
LDH, and therefore the number of lysed cells. Cells were plated in 96-well plates
at a density 10,000 cells/well in a Ca2+-free solution (See section 2.6.4.2 for
solution composition). Cell count was estimated using a hemocytometer (as
mentioned in the previous section). Cells were incubated for 40 minutes with or
without tested drug. A volume of CytoTox-ONE Reagent equal to the volume of
the solution containing the cells was then added and incubated for 10 minutes
after which a stop solution was added to each well and the fluorescent signal was
measured. 2 μl of Triton X-100 (9 % in water solution) per 100 μl original volume
was used as a positive control to produce maximum LDH release (cell lysis). All
average fluorescence values were subtracted from background fluorescence. The
fluorescence was recorded with an excitation wavelength of 560 nm and an
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Figure 2.7 Release of LDH from damaged cells: LDH release is measured by
supplying lactate, NAD+, and resazurin as substrates in the presence of
diaphorase. Generation of the fluorescent resorufin product is proportional to the
amount of LDH.
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emission wavelength of 590 nm and the percent toxicity of experimental drug was
calculated as follows:
Percent toxicity = 100 X (experimental-background) / (maximum LDH releasebackground)
2.10 Preparation of drugs and stock solutions
Experimental solutions were prepared from stocks immediately prior to
each experiment. Therefore, the cells were perfused with the freshly made bath
solutions containing the desired concentrations of the drugs.
2.10.1 Anandamide and methanandamide
AEA (MW 347.5) and metAEA (MW 361.56) were purchased from
Ascent Scientific, Cambridge, UK). AEA was already dissolved in ethanol (5
mg/ml). The concentration of AEA was 14.4 mM. From this stock solution, 7 µL
of AEA were taken to obtain a final test concentration of 1 µM. Similarly, 70 µL
of AEA were taken to achieve a final test concentration of 10 µM. Therefore, the
ethanol concentrations in the control and in presence of AEA were in the range of
0.007-0.07 % (v/v). MetAEA was also dissolved in ethanol (5 mg/ml) and
metAEA solution was prepared in the same way as AEA solution. Stock solutions
were kept at -20 °C until their use.
2.10.2 Cannabinoid receptor antagonists
AM251 (MW 555.24) and AM630 (MW 504.37) were purchased from
Ascent Scientific, Cambridge, UK). AM251 was dissolved in ethanol (8 mg/ml
ethanol) to make a final stock concentration of 14.4 mM. From this stock solution,
7 µL were taken to get a final test concentration of 1 µM. However, AM630 did
not dissolve easily in ethanol and larger volumes of ethanol were required to
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completely dissolve it (the highest concentration of stock solution of AM630 that
could be obtained was 2 mM). In this case, the final concentration of ethanol
would be 0.05 %. Therefore, AM630 was dissolved in dimethyl suphoxide
(DMSO) (7 mg/ml) to get a final stock concentration of 14.4 mM. From this stock
solution, 7 µL were taken to get a final test concentration of 1 µM. Stock solutions
of AM251 and AM630 were kept at -20 °C until their use.
SR141716 (MW 500.25) was purchased from Sigma-Aldrich (St. Louis,
MO, USA). SR144528 (MW 475.2) was obtained through NIDA drug supply
system (Baltimore, USA). Both drugs were dissolved in DMSO. The final
concentration of DMSO used in the experiments did not exceed 0.007 % (v/v)
(Bonz, et al., 2003).
2.10.3 Pertussis toxin
PTX was purchased from Sigma-Aldrich (St. Louis, MO, USA). PTX was
dissolved in distilled water and stock solution of 250 µg/500 ml was kept in the
refrigerator. Cells were incubated with PTX (2 µg/ml) for 3 hours at 37 °C
(control cells to this group were incubated in the same conditions with distilled
water only).
2.10.4 Indomethacin
Indomethacin (MW 357.8) was purchased from Tocris (Ballwin, MO,
USA) and a stock solution of indomethacin was prepared in ethanol. Cells were
incubated with 30 µM indomethacin for 30 minutes (control cells to this group
were incubated in the same conditions with ethanol only).
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2.10.5 URB597
The FAAH inhibitor URB597 (MW 338.4) was purchased from Tocris
(Ellisville, MO, USA). URB597 was dissolved in ethanol to make a 20 mM stock
solution. Cells were incubated with 1 µM URB597 for 45 minutes at 37 °C
(control cells to this group were incubated in the same conditions with ethanol
only).
2.10.6 N-ethylmaleimide
N-ethylmaleimide (NEM) (MW 125.3) was purchased from Sigma-Aldrich
(St. Louis, MO, USA). Stock solution of NEM (40 mM) was prepared in ethanol.
Cells were incubated with 50 µM NEM for 30 minutes at 37 °C (control cells to
this group were incubated in the same conditions with ethanol only).
2.10.7 Clenbuterol
Clenbuterol (MW 313.65) was purchased from Sigma-Aldrich (St. Louis,
MO, USA) and was dissolved in distilled water. Cells were perfused with
clenbuterol at a concentration of 30 µM.
2.10.8 BRL-37344
BRL-37344 (MW 385.82) was obtained from Tocris (Ballwin, MO, USA)
and was dissolved in distilled water. Cells were perfused with BRL37,344 at a
concentration of 1 µM.
All materials mentioned elsewhere were purchased from Sigma-Aldrich
(St. Louis, MO, USA).
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2.11 Data analysis
Each experiment was performed on several myocytes from different
hearts. The results of the experiments were expressed as mean ± standard error of
the mean (S.E.M.). Statistical significance was evaluated using paired t-test
(within the same cell analysis) or independent sample t-test and one way ANOVA
followed by Bonferroni Post-hoc analysis (for analysis of data from different
groups). Statistical analysis of the data was performed using Origin 7.0 software
(OriginLab Corp., Northampton, MA) and IBM SPSS statistics version 20. On all
graphs (*) denotes statistical significance with P<0.05, between specified values,
or if not specified to the respective control.
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3. RESULTS
3.1 Anandamide inhibits ventricular myocyte shortening
In initial control experiments and in line with earlier studies conducted
under similar conditions (Danziger, et al., 1991; Delbridge, et al., 2000; Bebarova,
et al., 2010), bath application of control solution (NT) containing ethanol at the
highest concentration used in contractility studies (0.07 % v/v; used as vehicle for
10 µM AEA) caused 18-20 % inhibition of the shortening (n=7-10; P<0.05
compared to 0 time point) in experiments lasting up to 20-25 minutes in response
to electrical stimulation (1Hz; 60 pulses delivered every 1 minute). No further run
down of the shortening amplitudes was observed. However, unless it was stated
otherwise, ethanol was included routinely in control solutions during shortening
and Ca2+ transient experiments.
In the first set of experiments, the effect of AEA on the contractility of
acutely isolated rat ventricular myocytes was tested. Figure 3.1A shows typical
records of shortening in an electrically stimulated (1 Hz) myocyte superfused with
either NT (containing 0.007 % ethanol in all experiments) or NT + 1 µM AEA.
The amplitude of shortening was significantly reduced up to 47.3 ± 2.6 % of
control (n=12-14; P<0.05) (Figure 3.1B), when the concentration of AEA was
increased in the range of 10 nM to 10 µM compared to NT.
The negative inotropic effect (decrease of shortening amplitudes) by AEA
could be due to degradation products of AEA such as AA. For this reason, we
investigated the effects of metAEA, a non hydrolyzable analog of AEA (Abadji, et
al., 1994) and URB597, an inhibitor of FAAH enzyme (Kathuria, et al., 2003).
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Figure 3.1 Effects of AEA and metAEA on ventricular myocyte shortening:
(A) Typical records of shortening in an electrically stimulated (1 Hz) ventricular
myocyte superfused with either NT or NT + 1 µM AEA and during washout with
NT. (B) Bar graph showing the mean amplitudes (AMP) of shortening expressed
as a percentage of control values, and in presence of AEA (1 nM to 10 µM). Data
are analyzed using ANOVA and are expressed as means ± S.E.M., n = 12-14
cells. * indicates statistically significant difference at the level of P < 0.05. (C)
Bar graph showing the mean amplitudes (AMP) of shortening expressed as a
percentage of control values, and in presence of metAEA (1 nM to 10 µM). Data
are analyzed using ANOVA and are expressed as means ± S.E.M., n = 7-8 cells. *
indicates statistically significant difference at the level of P < 0.05.
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In cardiomyocytes treated for 10 minutes with 0.1-10 µM metAEA (Figure
3.1C), the extent of inhibition was not significantly different from that of AEA
(n=7-8; P>0.05). Similarly, pretreatment with 1 µM URB597 for 45 minutes at 37
ºC (Kathuria, et al., 2003; Amoros, et al., 2010) did not alter the extent of AEA
inhibition (Figure 3.2A). In the absence and presence of URB597 treatment, AEA
(1 µM) inhibited myocyte shortening by 62.7 ± 8.4 % of controls and 68.2 ± 4.8 %
of controls, respectively. There were no statistically significant differences in the
inhibitory effect of AEA between control (NT+ 0.007 % ethanol after 45 minutes
pretreatment) and URB597 pretreated cells (n=9-11; P>0.05). We have also tested
whether cyclooxygenase products of AEA metabolites would mediate the
observed actions of this compound. The results indicated that the extent of
myocyte shortening was not significantly different after incubating the cells with
30 µM indomethacin, a cyclooxygenase inhibitor, for 30 minutes (n=8-11;
P>0.05) (Figure 3.2B).
Furthermore, the effect of synthetic cannabinoid WIN55,212-2 on
myocytes shortening was also tested. When compared to AEA, application of 1
μM WIN55,212-2 did not cause a significant alteration in the amplitudes of
myocyte shortening (n=7; P>0.05).
Among other contraction parameters measured, resting cell length (RCL)
was not significantly altered (n=12-14; P>0.05) by 10 minutes superfusion with
AEA (1 nM to 1 µM). However, increasing the concentration of AEA to 10 µM
caused a small but statistically significant reduction of RCL in about 60 % of cells
tested (n=12-14; P<0.05). Similarly, time to peak (TPK) shortening was
significantly reduced (n=12-14; P<0.05) to 90.2 ± 4.2 ms by 10 µM AEA
compared to 104.7 ± 1.7 ms in NT.
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Figure 3.2 Effects of preincubation with URB597 or indomethacin on AEAinduced inhibition of ventricular myocyte shortening: (A) Bar graph showing
the effect of AEA on the mean amplitude (AMP) of shortening expressed as
percentage of control values in NT containing 0.007 % ethanol or after 45 minutes
incubation with 1 µM URB597 at 37 ºC. Data are analyzed using ANOVA and are
expressed as means ± S.E.M., n=9-11 cells. (B) Bar graph showing the effect of
AEA on the mean amplitudes (AMP) of shortening expressed as percentage of
control values in NT containing 0.007 % ethanol or after 30 minutes incubation
with 30 µM indomethacin at 37 ºC. Data are analyzed using independent sample ttest and are expressed as means ± S.E.M., n=8-11 cells.
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3.2 Ventricular myocytes express cannabinoid receptors
In order to test for the involvement of cannabinoid receptors in the effect
of AEA on myocyte shortening, the expression of these receptors in the
ventricular tissue was confirmed by Western blot analysis. Figure 3.3 shows that
both CB1 and CB2 receptors (MW about 63 kDa and 40 kDa, respectively) are
expressed in the ventricular tissue of Wistar rats.
3.3 Cannabinoid receptors are not involved in the effect of anandamide on
myocyte shortening
To test whether the inhibitory effect of AEA on myocyte shortening is
mediated by the activation of cannabinoid receptors, the effects of established
antagonists of CB1 and CB2 receptors on AEA inhibition of shortening amplitudes
were studied. Two structurally different CB1 receptor antagonists (AM251 with a
Ki of 7.5 nM; Figure 3.4A and SR141716 with a Ki of 1.8 nM; Figure 3.4B)
(Pertwee, 2006; Shire, et al., 1999) and two CB2 receptor antagonists (AM630
with a Ki of 32.1 nM; Figure 3.4C and SR144528 with Ki of 0.6 nM; Figure 3.4D)
(Pertwee, 2006; Shire, et al., 1999) were tested. At 300 nM concentration, these
antagonists were not able to reverse the inhibitory effect of AEA on the shortening
amplitudes of cardiomyocytes (n=8-12; P>0.05).
Since the activation of both CB1 and CB2 receptors are mediated by Gi/o
subtypes of G-proteins (Pertwee, 2006), the effect of inhibitors of Gi/o proteins
such as PTX and N-ethylmaleimide (NEM) on AEA-induced inhibition of
cardiomyocyte shortening were examined (Figures 3.5A and 3.5B). Preincubation
of cardiomyocytes in either PTX (2 µg/ml, 3 hours at 37 ºC) or NEM (50 µM for
30 minutes at 37 ºC; (Oz, et al., 2007b)) did not alter the extent of AEA inhibition
of cardiomyocyte shortening (n=9-12; P>0.05).
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Figure 3.3 Expression of CB1 and CB2 receptors in rat heart: Expression of
CB1 and CB2 receptors in the heart of control Wistar rats (n= 3) were analyzed by
Western blotting.

89

Figure 3.4 Effects of cannabinoid receptor antagonists on AEA-induced
inhibition of cardiomyocyte shortening: Bar graphs showing the mean
amplitudes (AMP) of shortening expressed as a percentage of control values in
presence of CB1 receptor antagonist AM251 (A), CB1 receptor antagonist
SR141716 (B), CB2 receptor antagonist AM630 (C), and CB2 receptor antagonist
SR144528 (D). Data are analyzed using ANOVA and are expressed as means ±
S.E.M., n= 8-12 cells for each group. * indicates statistically significant difference
at the level of P < 0.05.

90

Figure 3.5 Effects of pertussis toxin and N-ethylmaleimide on AEA-induced
inhibition of cardiomyocyte shortening: (A) Bar graph showing the effect of
AEA on the mean amplitudes (AMP) of shortening expressed as a percentage of
control values and pertussis toxin pretreatment. (B) Bar graph showing the effect
of AEA on the mean amplitudes (AMP) of shortening expressed as a percentage
of control values and N-ethylmaleimide (NEM) pretreatment. Data are analyzed
using independent sample t-test and are expressed as means ± S.E.M., n = 9-12
cells.
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In order to test the effectiveness of the experimental protocols used to
investigate the role of G-proteins, the efficacy of PTX or NEM pretreatments on
clenbuterol (β2 adrenergic receptor agonist)-induced inhibition of cardiomyocyte
shortening was tested. In agreement with earlier studies (Siedlecka, et al., 2008), 3
hours pretreatment with 2 µg/ml PTX (Figure 3.6A) or 30 minutes pretreatment
with 50 µM NEM (Figure 3.6B) effectively blocked the inhibitory effect of the β 2
adrenoreceptor agonist clenbuterol (30 µM) on cardiomyocyte shortening (n=1012; P<0.05).
3.4 Anandamide inhibits intracellular Ca2+ transients
In these experiments, the effect of 10 minutes bath application of 1 µM
AEA on the resting intracellular Ca2+ levels and on the amplitudes and kinetics of
Ca2+ transients elicited by electrical-field stimulation were investigated. Typical
records of Ca2+ transients in a myocyte superfused with either NT or NT + 1 µM
AEA and during washout with NT are shown in Figure 3.7A. The effects of 1 µM
AEA on resting fura-2 ratio, TPK Ca2+ transient, THALF decay of Ca2+ transient,
and AMP of Ca2+ transients are shown in Figure 3.7B-E, respectively. Although,
AEA has been shown to alter intracellular Ca2+ levels in various types of cells [for
review, (Goodfellow and Glass, 2009)], application of 1 µM AEA for 10 minutes
did not cause a significant alteration in resting fura-2 ratio and TPK Ca2+ transient
(n=21-24 cells; P>0.05) (Figure 3.7B and C). However, THALF decay of the Ca2+
transients and AMP of the Ca2+ transients were significantly reduced by 1 µM
AEA to 118.9 ± 5.5 ms and 0.243 ± 0.032 fura-2 ratio units compared to 129.3 ±
5.2 ms (n=24 cells; P<0.05) and 0.326 ± 0.024 fura-2 ratio units (n =24 cells;
P<0.05) in controls, respectively (Figure 3.7D and E).

92

Figure 3.6 Effect of pretreatment with PTX or NEM on G-protein mediated
inhibition of cardiomyocyte shortening by clenbuterol: Data are analyzed using
independent sample t-test and are expressed as means ± S.E.M., n = 10-12 cells.
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Figure 3.7 Effects of AEA on amplitude and time-course of intracellular Ca 2+
in ventricular myocytes: (A) Typical records of Ca2+ transients in an electrically
stimulated (1 Hz) ventricular myocyte superfused with either NT or NT + 1 µM
AEA and during washout with NT; scale bar indicates 0.1 fura-2 ratio unit (RU).
Also shown resting fura-2 ratio (340/380 nm) (B), time to peak (TPK) Ca2+
transient (C), time to half (THALF) decay of the Ca2+ transient (D) and amplitude
(AMP) of the Ca2+ transient (E). Myocytes were maintained at 35-36 °C and
superfused with AEA for 10 minutes. Data are analyzed using paired t-test and are
expressed as means ± S.E.M., n=21-24 cells. * indicates statistically significant
difference at the level of P < 0.05.
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3.5 Anandamide has no effect on sarcoplasmic reticulum (SR) Ca 2+ transport
The effect of 1 µM AEA on Ca2+ transport was investigated in myocytes
exposed to 20 mM caffeine. Figure 3.8A shows a typical recording illustrating the
protocol used in these experiments. Initially, the myocyte was electrically
stimulated at 1 Hz. Electrical stimulation was then turned off for 5 seconds and
caffeine was applied for 10 seconds using a rapid solution exchanger device.
Electrical stimulation was then restarted and the recovery of intracellular Ca2+ was
recorded during a period of 60 seconds. Sarcoplasmic reticulum Ca2+ content was
assessed by measuring caffeine-evoked Ca2+ release (area under the caffeineevoked Ca2+ transient), and fractional release of Ca2+, by comparing the amplitude
of the electrically evoked steady-state Ca2+ transients with that after caffeine
application in the presence of either NT or NT + 1 µM AEA. Fractional release of
SR Ca2+ was not significantly altered in the presence of 1µM AEA compared to
NT (0.749 ± 0.024 in AEA versus 0.753 ± 0.028 in controls; n =23 cells; P>0.05;
Figure 3.8B). The area of caffeine-evoked Ca2+ transient (Figure 3.8C) and
recovery of the Ca2+ transient during electrical stimulation following application
of caffeine (Figure 3.8D) were also not significantly altered in myocytes exposed
to 1 µM AEA compared to control cells (n = 21-23 cells; P>0.05).
3.6 Anandamide has no effect on myofilament sensitivity to Ca 2+
The effects of AEA on myofilament sensitivity to Ca2+ were also
investigated. These experiments investigated whether AEA decreases the
mechanical responses by altering the affinity of the contractile machinery of the
ventricular myocytes to intracellular Ca2+ (Spurgeon, et al., 1992). A typical
record of myocyte shortening and fura-2 ratio and phase-plane diagrams of fura-2
ratio versus cell length in myocytes exposed to NT are shown in Figure 3.9A.
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Figure 3.8 Effect of AEA on sarcoplasmic reticulum Ca 2+ transport: (A)
Typical record illustrating the effects of electrical stimulation (ES) and rapid
application of caffeine on fura-2 ratio in a rat ventricular myocyte. Also shown are
mean amplitude of SR fractional release of Ca2+ (B), area under the caffeineevoked Ca2+ transient (C) and recovery of electrically evoked intracellular Ca2+
after application of caffeine (D). Data are analyzed using paired t-test and are
expressed as means ± S.E.M., n = 21-23 cells.
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Figure 3.9 Effect of AEA on myofilament sensitivity to Ca2+: (A) Typical
records of myocyte shortening, fura-2 ratio and phase-plane diagrams of fura-2
ratio vs. cell length in a myocyte exposed to NT. The arrow indicates the region
where the gradient was measured. B-D show the effect of 1 µM AEA on the mean
gradient of the fura-2–cell length trajectory during late relaxation of the twitch
contraction during the periods 500-600 (B), 500-700 (C) and 500-800 ms (D)
Data are analyzed using paired t-test and are expressed as means ± S.E.M., n = 2330 cells.
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The gradient of the trajectory reflects the relative myofilament response to
Ca2+ and hence, has been used as a measure of myofilament sensitivity to Ca2+
(Spurgeon, et al., 1992). The gradients of the fura-2-cell length trajectory during
late relaxation of the twitch contraction, measured during the periods 500-600 ms
(Figure 3.9B), 500-700 ms (Figure 3.9C), and 500–800 ms (Figure 3.9D), were
not significantly altered in the presence of 1 µM AEA, suggesting that
myofilament sensitivity to Ca2+ is not reduced by AEA (n = 23-30 cells; P>0.05).
3.7 Anandamide suppresses the action potentials in ventricular myocytes
Generation of the cardiac AP requires a specific temporal activation
pattern of several ion channels. Anandamide has been shown to influence the
functional properties of these channels either directly or indirectly [for reviews,
(Oz, 2006; Goodfellow and Glass, 2009)]. Therefore, in this set of experiments,
the effect of AEA on cardiac APs was investigated. In agreement with earlier
studies in rat cardiomyocytes (Danziger, et al., 1991; Delbridge, et al., 2000;
Bebarova, et al., 2010), AP waveforms remained unchanged in the presence of
ethanol concentrations up to 0.07 % (v/v).
Patch-clamped cardiomyocytes were exposed to AEA while continuously
monitoring their Vrest and APs in the current clamp mode. The generation of APs
was evoked by 0.9-1 nA depolarizing current pulses of 4 ms duration applied at a
frequency of 0.2 Hz. A typical experimental protocol included: 1) the
establishment of the whole-cell configuration, 2) 4 to 5 minute dialysis of the
myocytes with pipette solution to ensure equilibrium conditions between the
pipette solution and intracellular milieu, 3) recording of the myocytes baseline
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electrical activity following stabilization of Vrest and AP parameters, 4) exposure
of the myocytes to AEA for 10 to 15 minutes, and 5) washout of AEA.
In initial experiments, effects of AEA were tested on the passive
membrane properties of cardiomyocytes. The passive properties of the ventricular
cells from controls were not significantly different from those of the AEA-treated
cells. Resting membrane potentials (mean ± SEM) were -76.3 ± 1.7, and -74.2 ±
1.6 mV in control (n=11) and AEA treated (n=14) myocytes, respectively. The
mean cell capacitance in the control group of cells was 109.6 ± 12.8 pF, whereas
in the AEA treated cells was 104.7 ± 11.6 pF. The input resistance was 82.3 ±
13.4 MΩ in control cells and 85.6 ± 11.8 MΩ in AEA treated cells. In control
cells, these passive membrane properties were not altered significantly in
experiments lasting up to 25 to 30 minutes.
In agreement with earlier studies in rat ventricular myocytes [for a review,
(Antzelevitch, et al., 1991)], two main types of waveforms were observed
according to the duration of their APs; endocardial (with long AP durations,
Figure 3.10A; 44.6 ± 2.9 ms; n=23 cells) and epicardial (with short AP durations;
Figure 3.10B; 14.9 ± 1.6 ms; n=26 cells) myocytes. Resting membrane potentials
were -77.6 ± 1.3 mV in endocardial cells, and -78.5 ± 1.4 mV in epicardial cells
(Figure 3.11A). Similar to earlier findings (Antzelevitch, et al., 1991), the
amplitudes of APs (122.6 ± 8.9 mV versus 110.7 ± 7.1 mV) (Figure 3.11B) and
maximal rate of rise (dV/dtmax) values (177.3 ± 8.4 V/s versus 141.6 ± 7.2 V/s)
(Figure 3.11C) in endocardial cells were higher than those of epicardial cells
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Figure 3.10 Effect of AEA on the excitability of ventricular myocytes: Representative recordings of APs in controls (dark grey area), in the
presence of 1 μM AEA (light grey area) and after washout (striped area) in ventricular endocardial (A) and epicardial (B) myocytes; the insets
on panels A and B show the time course of the action potential duration (APD60) and resting potential (Vrest) changes in response to AEA
application (indicated by horizontal bars).
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Figure 3.11 Summary of the effect of AEA on the amplitude and the shape of
APs in cardiomyocytes: Quantification of the changes in Vrest (A), AP amplitude
(B), AP maximal rate of rise (C) and AP duration (D), characterized by APD60 in
controls (dark grey bars) and in response to 0.1 μM (cross hatched bars) or 1 μM
AEA (light grey bars). Data are analyzed using ANOVA and are expressed as
means ± S.E.M. from 8 to 12 myocytes for each group. * indicates statistically
significant difference at the level of P < 0.05.
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At concentrations of 0.1 µM and 1µM, AEA consistently shortened the
duration of AP in both cell types (measured at 60 % of repolarization, APD 60;
Figure 3.11D), with a hyperpolarizing shift in Vrest (Figure 3.11A). Changes in AP
shortening in response to AEA (1 µM) application were noticeable within 1-2
minutes (insets to Figures 3.10A and 3.10B). Recoveries were usually partial and
required longer time. Similar effect of AEA was observed in 5 cells recorded at
physiological temperatures (35-36 °C). APD60 decreased from 33.8 ± 4.6 ms in
controls to 21.4 ± 3.2 ms in the presence of AEA (n=5; P<0.05).
Effects of AEA on Vrest (Figure 3.11A), and APD60 (Figure 3.11D)
reached a statistically significant level at 1 µM AEA (n=8-12 cells for each group;
P<0.05). However, AP amplitude (Figure 3.11B) and dV/dtmax of AP (Figure
3.11C) were not altered significantly in both types of cells at 0.1 µM and 1 µM
AEA (n=10-12 cells for each group; P>0.05).
At higher concentration (10 µM), AEA caused 5-10 mV depolarization
(Figures 3.12A, 3.12B and 3.13A) in endocardial (n=18 cells; P<0.05) and
epicardial cells (n=24 cells; P<0.05) and decreased significantly the AP
amplitudes and dV/dtmax in both types of myocytes (Figures 3.13B and 3.13C;
n=18-24 cells; P<0.05). AEA (10 µM) also caused a significant decrease in APD60
(Figure 3.13D). However, in a subgroup of endocardial (5 out of 18) and
epicardial (4 out of 24) cells, AEA, although caused a significant depolarization
and a significant decrease in AP amplitude and maximum rate of rise of AP, it did
not alter APD60 values significantly.
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Figure 3.12 Effects of high concentration of AEA on the excitability of ventricular myocytes: Representative recordings of APs in controls
(dark grey area), in the presence of 10 μM AEA (light grey area) and after washout (striped area) in ventricular endocardial (A) and epicardial
(B) myocytes; the insets on panels A and B show the time course of the action potential duration (APD 60) and resting potential (Vrest) changes in
response to AEA application (indicated by horizontal bars).
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Figure 3.13 Summary of the effect of high concentration of AEA on the
amplitude and the shape of APs in cardiomyocytes: Quantification of the
changes in Vrest (A), AP amplitude (B) AP maximal rate of rise (C) and AP
duration (D), characterized by APD60 in controls (dark grey bars) and in response
to 10 μM AEA (light grey bars). Data are analyzed using paired t-test and are
expressed as means ± S.E.M. from 18 to 24 myocytes (for A-C) and from 13 to 20
(for D). * indicates statistically significant difference at the level of P < 0.05.
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3.8 Cannabinoid receptors are not involved in the effect of anandamide on
the action potentials in ventricular myocytes
In these experiments, the effects of CB1 receptor antagonist AM251 (0.3
µM) and CB2 receptor antagonist AM630 (0.3 µM) on AEA-induced changes in
the AP duration of endocardial and epicardial myocytes were investigated. The
effect of AEA on APD60 remained unaltered in the presence of AM251 (n=5-7
cells; P>0.05; Figure 3.14A). Similarly, pretreatment with AM630 did not cause a
significant effect on AEA-induced changes in APD60 in both endocardial and
epicardial myocytes (n=5-7 cells; P>0.05; Figure 13.4B). Since the actions of
cannabinoid receptors (CB1 and CB2) are mediated by the activation of Gi/o
proteins sensitive to PTX treatment, we tested whether PTX pretreatment (2
µg/ml, 3 hours at 37 ºC) alters AEA-induced changes in AP duration in
endocardial and epicardial myocytes. PTX did not cause a significant alteration in
the effects of AEA on both endocardial and epicardial myocytes (n=5-7 cells;
P>0.05; Figure 3.14C).
3.9 Anandamide inhibits voltage-dependent Na+ channels in ventricular
myocytes
Previous studies have indicated that AEA has significant antiarrhythmic
effects (Ugdyzhekova, et al., 2001; Li, et al., 2009). Since voltage-activated
inward Na+ (INa) and Ca2+ (IL,Ca) currents are the major ion currents shaping the
action potential in ventricular myocytes, we have conducted a series of
experiments under conditions that enable reliable isolation of either INa or IL,Ca in
voltage-clamp mode. In the first set of experiments, INa was typically elicited by
pulses from -80 mV to +60 mV for 50 ms. Figure 3.15A shows recordings of INa
in ventricular myocytes before and after application of 10 µM AEA.
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3.14 Effect of cannabinoid receptor antagonists and PTX pretreatment on
AEA-induced changes in myocyte excitability: (A) Effect of CB1 receptor
antagonist AM251 (0.3 µM) on AEA-induced changes in APD60 in endocardial
and epicardial myocytes. APD60 was presented in control and in the presence of 1
µM AEA, 0.3µM AM251, and 1 µM AEA + 0.3µM AM251. (B) Effect of CB2
receptor antagonist AM630 (0.3 µM) on AEA-induced changes in APD60 in
endocardial and epicardial myocytes. APD60 was presented in control and in the
presence of 1 µM AEA, 0.3 µM AM630, and 1 µM AEA + 0.3 µM AM630. (C)
Effect of PTX treatment on AEA-induced changes in APD60 in endocardial and
epicardial myocytes. Changes are presented in control, in presence of 1 µM AEA,
in control + PTX, and in presence of 1µM AEA + PTX. Data are analyzed using
ANOVA and are expressed as means ± S.E.M., from 5 to 7 myocytes of each
type; * indicate statistically significant difference at the level of P<0.05.
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Figure 3.15 Effect of AEA on INa in rat ventricular myocytes: (A) AEA
inhibits INa recorded using whole cell voltage clamp mode of patch clamp
technique. INa was recorded during 50 ms voltage pulses to -20 mV from a holding
potential of -80 mV. Current traces were recorded before (control) and after 10
minutes application of 10 μM AEA. (B) Maximal currents of VGSCs presented as
a function of time in the presence of vehicle (0.07 % ethanol) and 10 μM AEA
(n=5-6 cells). (C) Representative recordings of INa in response to the depicted
pulse protocol under control conditions and after application of 10 μM AEA. (D)
Normalized and averaged I-V relationships of control INa (filled circles) and INa in
the presence of 10 μM AEA (open circles) determined by applying a series of step
depolarizing pulses from -80 mV to +60 mV in 10 mV increments for a duration
of 50 ms. Data are analyzed using paired t-test and are expressed as means ±
S.E.M. from 5 to 7 cells.
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The effect of AEA was detectable within 2-3 minutes and reached a steady-state
level within 10-15 minutes. The recovery was partial during the experiments
lasting up to 25 to 30 minutes (Figure 3.15B).
With 40 mМ Na+ outside and Cs+ as the major intracellular cation, inward
INa in response to incremental step depolarizations (Vm, 10 mV increment) applied
from a holding potential Vh= -80 mV, INa started to activate at Vm= -60 mV, and
reached maximal amplitude at about Vm=-30 mV. At more positive potentials the
inward current decreased, reversing its direction at an apparent reversal potential
(Vrev) of around +60 mV. Traces of INa in the absence and presence of 10 µM
AEA were presented in Figure 3.15C. AEA inhibited INa without causing
significant changes in the I-V relationship. The I-V relationship for INa is
illustrated in Figure 3.15D. AEA inhibited INa without changing the threshold,
peak and reversal potentials.
In this study, AEA was dissolved in ethanol, and therefore, we have tested
the effect of ethanol as a vehicle. In agreement with earlier studies (Danziger, et
al., 1991; Bebarova, et al., 2010), our results indicate that maximal amplitudes of
INa were altered after 10 minutes vehicle application in experiments lasting up to
20 to 25 minutes (Figure 3.16A). Due to the effect of vehicle, we have tested each
concentration of AEA and vehicle separately and plotted the concentration
response curve after subtraction of vehicle effect. The effect of increasing AEA
and corresponding ethanol concentrations and corrected concentration-response
curve were presented in Figure 3.16B.
In order to exclude the possibility of the involvement of degradation
products of AEA in the inhibition of INa, the effect of 10 µM metAEA was tested.
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Figure 3.16 Effect of increasing AEA and vehicle concentrations on INa
recorded in rat ventricular myocytes: (A) Effects of AEA (0.1 to 30 µM) and
corresponding vehicle concentrations on the maximal amplitudes of INa currents.
Data are analyzed using paired t-test and are expressed as means ± S.E.M. from 5
to 7 cells. (B) Corrected concentration response curve for the inhibitory effect of
AEA on INa. The amount of inhibition induced by the vehicle was subtracted from
the AEA-induced inhibition at corresponding AEA concentrations. Data was fit
with logistic equation using Origin data analysis software.
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10 minute application of metAEA caused a significant inhibition of INa (36 ± 4 %
of controls; n=5 cells; P>0.05).
Steady-state activation (SSA) curves of INa, before and after AEA
application, were derived by fitting the respective I-V relationships with the
product of Boltzmann equation (Figure 3.17A). This allowed us to determine if
AEA influences the parameters of INa SSA: the voltage of half-maximal activation
(V1/2) and slope factor (k). In controls, V1/2 and k values were -45.2 mV and 7.1
mV, respectively. In the presence of 10 µM AEA, V1/2 and k values were -42.3
mV, and 7.5 mV. There were no statistically significant differences between
controls and AEA-treated cells (n=8-10 cells; P>0.05).
In order to determine if AEA influences the properties of inactivation of
VGSCs, SSI dependencies of INa in the absence and presence of AEA were
compared. Steady state inactivation curves were acquired using a standard voltage
protocol consisting of prolonged (400 ms) conditioning pre-pulse to various Vm,
in the range of -100 mV to +70 mV, which was immediately followed by a
constant INa activating test pulse to Vm= -20 mV. Steady state inactivationdependency was plotted as normalized amplitude of INa at Vm= -20 mV against the
value of conditioning Vm The fit of the obtained data points using the Boltzmann
equation (Figure 3.17B) has indicated that under control conditions, V1/2 and k
values were -70.2 mV and -5.8 mV, respectively. In the presence of 10 μM AEA,
V1/2 and K values were -81.4 mV and -5.1 mV, respectively. Thus, AEA induced a
significant hyperpolarizing shift in the voltage-dependence of SSI of cardiac
VGSCs (-11.4 mV; P<0.05). Comparison of INa currents, in the absence and
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Figure 3.17 Effect of AEA on steady state activation and inactivation of INa in
rat ventricular myocytes: (A) Steady-state activation (SSA) and (B) steady-state
inactivation (SSI) curves of INa in the absence (filled circles) and presence of 1
μM AEA (open circles). (C) Voltage-dependence of INa inactivation time constant
(τi) under control conditions (filled circles) and in the presence of 1 μM AEA
(open circles). Data are analyzed using paired t-test and are expressed as means ±
S.E.M., are from 7 cells. * indicates statistically significant difference at the level
of P < 0.05.
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presence of AEA, revealed noticeable acceleration of the current's inactivation
kinetics by AEA. Quantification of the time constant of INa inactivation (τi), by
fitting the currents' decay phase with exponential functions, showed that AEA (10
μM) significantly reduced τi in the range of Vm between -50 mV and +20 mV
(Figure 3.17C). Furthermore, the results of this study show that the inhibitory
effect of AEA on the maximal amplitudes of INa was not significantly affected by
PTX pretreatment (Figure 3.18).
3.10 Anandamide inhibits voltage-dependent Ca2+ channels in ventricular
myocytes
The effect of AEA on the L-type Ca2+ currents (IL,Ca) was also tested.
Figure 3.19A shows a typical record of IL,Ca elicited by applying a single 300 ms
voltage pulse to +10 mV from a holding potential of -50 mV in rat ventricular
myocyte before and after 10 minutes superfusion with 1µM AEA. Time course of
the effect of AEA on the density of IL,Ca was presented in Figure 3.19B. The
effects of AЕА were also investigated on the biophysical properties of IL,Ca in rat
ventricular myocytes. L-type Ca2+ current was recorded in the presence of
intracellular Cs+ and extracellular TEA+ to suppress K+ currents, while retaining
95 mM Na+ in the extracellular solution. Elimination of contaminating Na+ current
during recording of IL,Ca was achieved by applying voltage step-pulses from
relatively depolarized Vh of -50 mV, which produced steady-state INa inactivation
(Voitychuk, et al., 2012). As evident from original recordings and I-V
relationships (Figures 3.19C and D), IL,Ca had a much slower kinetics in response
to step depolarization, and activated at more positive potentials than INa: it started
to appear at Vm= -30 mV, reached maximum at around Vm= +10 mV, and
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Figure 3.18 Effect of PTX pretreatment on AEA inhibition of the maximal INa
amplitudes. Black bars indicate controls. Data are analyzed using independent
sample t-test and are expressed as means ± S.E.M., from 6 to 8 cells.
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Figure 3.19 Effect of AEA on IL,Ca in rat ventricular myocytes: (A) AEA
inhibits IL,Ca recorded using whole-cell voltage-clamp mode of patch clamp
technique. IL,Ca was recorded during 300 ms voltage pulses to +10 mV from a
holding potential of -50 mV. Current traces recorded before (control) and after 10
minutes application of 1 μM AEA. (B) Maximal currents presented as a function
of time in the presence of vehicle (0.007 % ethanol) and 1 μM AEA (n=5 cells).
(C) Representative recordings of IL,Ca in response to the depicted pulse protocol
under control conditions and after application of 1 μM AEA. (D) Normalized and
averaged I-V relationships of control IL,Ca (open circles) and IL,Ca in the presence of
1μM AEA (filled circles) determined by applying a series of step depolarizing
pulses from-70mV to +70 mV in 10 mV increments for a duration of 300 ms. Data
are analyzed using paired t-test and are expressed as means ± S.E.M. from 5 to 7
cells.
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decreased at higher voltages approaching zero at about Vm= +60 mV (Figure
3.19D).
Current density of IL,Ca was also altered after 10 minutes application of
ethanol in experiments lasting up to 20 to 25 minutes. Effects of increasing AEA
and corresponding ethanol concentrations on IL,Ca and corrected concentrationresponse curve were presented in Figure 3.20.
In order to exclude the possibility of involvement of degradation products
of AEA in the inhibition of IL,Ca, the effect of 1 µM metAEA was tested. MetAEA
caused a significant inhibition of Ca2+ currents (46 ± 4% inhibition of controls;
n=5 cells; P<0.05). In addition, the effect of FAAH inhibition on AEA-induced
inhibitory effect was tested. Pretreatment with 1 µM URB597 for 45 minutes at 37
ºC (controls incubated with 0.007 % ethanol alone) did not alter the extent of AEA
inhibition of L-type Ca2+ currents. In the absence and presence of URB597, AEA
(1 µM) inhibited L-type Ca2+ currents to 32.7 ± 3.6 % of and 35.3 ± 4.2 % of
controls, respectively (n=5-7; P>0.05).
AEA produced a depolarizing shift of IL,Ca SSA by 12.6 mV (i.e., V1/2= 9.4 ± 0.3 mV, in control, to V1/2= +3.2 ± 0.2 mV, in the presence of AEA) and
hyperpolarizing shift of IL,Ca SSI by 4.3 mV (i.e., from V1/2= -18.9 ± 0.1 mV, in
control, to V1/2= -23.2 ± 0.1 mV, in the presence of AEA) with little influence on
the slopes of respective dependencies (k= 7. 2 ± 0.4 mV and k= -5.3 ± 0.3 mV for
the control activation and inactivation, respectively, vs. k= 6.9 ± 0.3 mV and k= 5.1±0.2 mV for the AEA-modified activation and inactivation, respectively),
which altogether resulted in the notable reduction of I

L,Ca

“window current”

responsible for the stationary Ca2+ entry in the range of membrane
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Figure 3.20 Effects of increasing AEA and vehicle concentrations on IL,Ca
recorded in rat ventricular myocytes: (A) Effects of AEA (0.1 to 30 µM) and
corresponding vehicle concentrations on the maximal amplitudes of IL,Ca. Data are
analyzed using paired t-test and are expressed as means ± S.E.M., from 5 to 7
cells. (B) Corrected concentration response curve for the inhibitory effect of AEA
on IL,Ca. The amount of inhibition induced by the vehicle was subtracted from
AEA-induced inhibition at corresponding AEA concentrations. Data was fit with
logistic equation using Origin data analysis software.
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potentials from -40 mV to +10 mV (Figure 3.21A and 3.21B). Thus, the
mechanism of AEA action on cardiac L-type VGCC most likely involves
influence on channel gating that reduces “window current” as well as partial
blockade of the ion-conducting pathway that decreases current amplitude.
In line with earlier reports (Soldatov, et al., 1998), kinetic analysis of I L,Ca
currents were fit to double-exponential function with fast (τ f) and slow (τs)
inactivation time constants. Comparison of IL,Ca currents in the absence and
presence of AEA revealed noticeable acceleration of the current's inactivation
kinetics by AEA. Quantification of the time constants of IL,Ca inactivation showed
that AEA (1μM) significantly reduced τi in the range of Vm -20 mV and +10 mV
(Figure 3.21C).
In earlier electrophysiological studies, sidedness of AEA actions on
various ion channels has been reported (Oz, 2006). For this reason, the effect of
intracellular application of AEA by including AEA (1µM) inside the patch
electrode was tested (Figure 3.22). The extent of AEA inhibition (compared after
15 minutes of AEA exposure) was not significantly different between intracellular
and extracellular AEA applications (n=11-14 cells; P>0.05).
In order to test if the modulation of Ca2+ binding site can mediate the
effect of AEA on the inactivation kinetics of L-type VGCCs, extracellular Ca2+
was replaced with Ba2+ and the effect of AEA on Ba2+ currents (IBa) through Ltype VGCCs was tested. In line with earlier studies (Soldatov, et al., 1998),
inactivation of IBa fit to mono-exponential decay function (Figure 3.23A) with
significant voltage-dependency. In the presence of AEA, inactivation time
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Figure 3.21 Effect of AEA on steady state activation and inactivation of IL,Ca
in rat ventricular myocytes: (A) Steady-state activation (SSA) and (B) steadystate inactivation (SSI) curves of IL,Ca in the absence (filled circles) and presence
of 1 μM AEA (open circles). (C) Voltage-dependent fast (triangles) and slow
(circles) inactivation time constants (τi) of IL,Ca under control conditions (filled
circles and triangles) and in the presence of 1μM AEA (open circles and
triangles). Data are analyzed using paired t-test and are expressed as means ±
SEM. from 5-6 cells. * indicates statistically significant difference at the level of P
< 0.05.
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Figure 3.22 Effect of sidedness of AEA application on IL,Ca in rat ventricular
myocytes: Comparison of the intracellular and extracellular application of AEA
on the maximal inhibition of IL,Ca. Data are analyzed using independent sample ttest and are expressed as means ± S.E.M. from 11-14 cells.
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constant (Figure 3.23A and 3.23B), and the maximal amplitudes of IBa were
significantly inhibited compared to control values (n=7-8 cells; P<0.05).
Since the known cannabinoid receptors CB1 and CB2 [for a review,
(Pertwee, et al., 2010)] are coupled to PTX sensitive Gi/o type G-proteins, we have
tested whether the inhibitory effects of AEA on L-type VGCCs are mediated by
the activation of cannabinoid receptors. In the presence of 0.3 µM AM251 and 0.3
µM AM630, AEA (1µM) inhibition of IL,Ca remained unaltered. Application of
AM251 or AM630 alone did not have a significant effect on the amplitudes of
IL,Ca (Figure 3.24) (n=6-9 cells; P>0.05). Furthermore, the results of this study
show that the inhibitory effect of AEA on the maximal amplitudes of I L,Ca was not
affected by PTX pretreatment (Figure 3.25).
In positive control experiments, PTX, as it has been reported earlier
(Zhang, et al., 2005), effectively attenuated the inhibitory actions of BRL-37344, a
β3 adrenergic receptor agonist, on IL,Ca recorded in ventricular myocytes (Figures
3.26A and 3.26B) indicating that G-proteins are functionally coupled to their
target receptors.
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Figure 3.23 Effect of AEA on Ba2+ currents mediated by L-type VGCCs: (A) Traces of normalized Ca2+ and Ba2+ currents through L-type
VGCCs. Normalized Ba2+ current in the presence 1 µM AEA is also presented in the figure. (B) Effect of 1 µM AEA on the maximal amplitudes
and the inactivation kinetics of Ba2+ currents. Data are analyzed using paired t-test and are expressed as means ± S.E.M. from 7-8 cells.*
indicates statistically significant difference at the level of P <0.05.
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Figure 3.24 Effects of cannabinoid receptor antagonists on AEA inhibition of
L-type VGCCs: Effects of CB1 antagonist AM251 (0.3 µM) and CB2 antagonist
AM630 (0.3 µM) on AEA (1 µM) inhibition of IL,Ca. Data are analyzed using
ANOVA and are expressed as means ± S.E.M. from 6-9 cells.* indicates
statistically significant difference at the level of P <0.05.
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Figure 3.25 Effects of PTX pretreatment on AEA inhibition of L-type
VGCCs: Percent inhibition of IL,Ca after vehicle (distilled water) and PTX (2
µg/µl, 3hours). Data are analyzed using independent sample t-test and are
expressed as means ± S.E.M. from 6-8 cells.
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Figure 3.26 Effect of PTX pretreatment on BRL-37344 inhibition of IL,Ca
recorded in rat ventricular myocytes: (A) Records of currents presenting the
effect of BRL-37344, on IL,Ca in the absence and presence of PTX (2 µg/ml for 3
hours in 37 °C) pretreatment. Records were obtained by applying a step
depolarizing pulse from -50 mV to +10 mV for duration of 300 ms (B)
Presentation of results on the effect of PTX pretreatment on BRL-37344 inhibition
of IL,Ca. Data are analyzed using independent sample t-test and are expressed as
means ± S.E.M. from 5-7 cells.* indicates statistically significant difference at the
level of P<0.05.
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3.11 Anandamide inhibits Na +/Ca2+ exchanger in ventricular myocytes
Currents mediated by NCX1 were elicited by a descending voltage ramp
pulses applied between +100 mV and -100 mV (dV/dt = 0.1 V/s) from a holding
potential of −40 mV for 2 seconds. In order to verify that the currents recorded in
our experimental conditions are mediated by the NCX1, Ni2+ (10 mM) was used
routinely at the end of each experiment to determine the Ni2+-sensitive NCX1
current (Figure 3.27A and 3.27B). Bath application of Ni2+ for 5 minutes
reversibly suppressed INCX1, indicating that these currents are mediated by NCX1
in cardiomyocytes (Figures 3.27A and 3.27B). Command pulses were applied
every 15 seconds, and amplitudes of currents at +100 mV and -100 mV were
plotted as a function of time (Figure 3.27A). Anandamide largely attenuated both
the outward and inward components of Ni2+-sensitive current. The effect of AEA
was detectable at 2-3 minutes and reached a steady-state level within 5 minutes.
Within the time period of our experiment, the recovery was partial. Figure 3.27B
shows representative current traces in control solution, in the presence of AEA (10
µM) and in the presence of Ni2+ (10 mM). In this experiment, AEA was dissolved
in ethanol. The maximal amplitudes of INCX1 were not altered by 10 to 15 minutes
application of ethanol up to the concentration of 0.07% (V/V; n=6).
Figure 3.27C shows the mean I-V relationships for Ni2+-sensitive INCX1 in
control and in the presence of 10 µM AEA. INCX1 was calculated by subtracting
the currents recorded in Ni2+ from the current recorded without Ni2+. Evaluation of
the AEA inhibition of INCX1 at different membrane potentials (Figure 3.27D)
indicated that AEA inhibits both outward and inward components of INCX1 equally.
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Figure 3.27 Effect of AEA on INCX1 in rat ventricular myocytes: AEA inhibits
INCX1 recorded using whole cell voltage clamp mode of patch clamp technique.
(A) Time course of the effects of AEA on the inward and outward INCX1 recorded
in a cardiomyocyte. INCX1 was elicited by 2 seconds voltage ramps from +100 mV
to -100 mV every 15 seconds. Amplitudes of currents recorded at +100 mV and 100 mV were presented as a function of time. Horizontal bars indicate drug
application times. Arrows correspond to the time points for the currents shown in
Figure 3.27B (B) Current traces were recorded in control, after 5 minutes
application of 10 μM AEA, and following 10 mM Ni2+ for 5 minutes. (C) Mean IV relationship of NCX1 in the absence and presence of 10 µM AEA. Data points
(mean ± S.E.M.) are from 7 cells. (D) Quantification of the extent of AEA
inhibition of INCX1 at different membrane potentials. Data points (mean ± S.E.M.)
are from 6 cells. Paired t-test was used to compare the amplitude of current
currents recorded at +100 mV and -100 mV.* indicates statistically significant
difference at the level of P<0.05.
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Collectively, these observations indicate that, AEA (10 µM) exerts an inhibitory
effect on NCX1 in ventricular myocytes.
The effect of increasing AEA concentrations on the outward (measured at
+100 mV) components of INCX1 was demonstrated in Figure 3.28. AEA inhibited
INCX1 in a concentration-dependent manner with IC50 values of 4.7 µM. The effect
of metAEA was also tested to avoid the likely confounding effects of degradation
products and oxygenated metabolites on NCX1. At a concentration of 10 μM,
metAEA also caused a significant inhibition of exchanger current (Figure 3.29A).
Furthermore, the effect of AEA on NCX1 in the presence of the specific FAAH
inhibitor URB597 was also tested. After incubation of cardiomyocytes with 1 µM
URB597 for 1 hour, AEA continued to inhibit the function of NCX1 (Figure
3.29B) further suggesting that the intact AEA molecule, but not the degredation
products, mediates its effect on the exchanger.
In the presence of 1 µM AM251 and 1 µM AM630, AEA (10 µM)
inhibition of INCX1 remained unaltered (n=6-8, Figure 3.30). In addition, the results
of this study show that the inhibitory effect of AEA on the maximal amplitudes of
INCX1 was not affected by PTX pretreatment (Figure 3.31A). In positive control
experiments (section 3.10), PTX, as it has been reported earlier (Zhang, et al.,
2005), effectively attenuated the inhibitory actions of BRL-37344, a β3 adrenergic
receptor agonist, on L-type VGCCs recorded in ventricular myocytes (Figure
3.26). GDP-β-S is also commonly used to inhibit the responses mediated by the
activation of G-protein receptors (Bondarenko, et al., 2013). For this reason, the
effect of AEA in the presence of GDP-β-S in intracellular solution was tested.
After the inclusion of GDP-β-S (1mM) in pipette solution, AEA continued to
inhibit NCX1 (Figure 3.31B).
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Figure 3.28 Effect of increasing AEA concentration on INCX1 in rat
ventricular myocytes: AEA inhibits INCX1 in a concentration-dependent manner.
Ni2+-sensitive current was measured at +100 mV. Data points (mean ± S.E.M.) are
from 6 to 8 cells.
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Figure 3.29 Effects of metAEA and URB597 on INCX1 in rat ventricular
myocytes: (A) Effect of 10 µM metAEA on net INCX1 (after subtraction of current
in10 mM Ni2+). Data points (mean ± S.E.M.) are from 5 cells. (B) Effect of 10 µM
AEA on INCX1 in cardiomyocytes incubated with 1 µM URB597 for 1 hour. Data
points (mean ± S.E.M.) are from 6 cells. Paired t-test was used to compare the
amplitude of current currents recorded at +100 mV and -100 mV.* indicates
statistically significant difference at the level of P<0.05.
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Figure 3.30 Effects of cannabinoid receptor antagonists on AEA inhibition of
INCX1 recorded in ventricular cardiomyocytes: (A) Time course of the effects of
CB1 antagonist AM251 (1 µM) on AEA inhibition of INCX1. (B) Effect of 1 µM
AM251 on AEA inhibition of net NCX1 current at different membrane potentials
(after subtraction of current in 10 mM Ni2+). (C) Time course of the effects of CB2
antagonist AM630 (1 µM) on AEA inhibition of INCX1 (D) Time course of the
effect of 1 µM AM630 on AEA inhibition of INCX1 at different membrane
potentials (after subtraction of current in 10 mM Ni2+). Data points (mean ±
S.E.M.) are from 6-8 cells. Paired t-test was used to compare the amplitude of
current currents recorded at +100 mV and -100 mV.* indicates statistically
significant difference at the level of P<0.05.
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Figure 3.31 Effects of PTX pretreatment and intracellular application of
GDP-β-S on AEA inhibition of INCX1 in ventricular cardiomyocytes: (A)
Effect of PTX pretreatment on AEA inhibition of INCX1. Amplitudes of inward and
outward components of INCX1 were measured at +100 mV and -100 mV,
respectively. Data points (mean ± S.E.M.) are from 6 cells. (B) Effect of GDP-β-S
inclusion in the patching pipette on AEA inhibition of INCX1. Amplitudes of
inward and outward components of INCX1 were measured at +100 mV and -100
mV, respectively. Data points (mean ± S.E.M.) are from 7 cells. Data are analyzed
using paired t-test. * indicates statistically different from the control values at the
level of P<0.05.
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3.12 Anandamide has no effect on cell viability in ventricular myocytes
Cell viability was assessed using the MTT assay. Cell death was induced
by 1 % Triton X-100 (Abood, et al., 2001). The effect of AEA (10 µM) on cell
viability of ventricular cardiomyocytes was examined after 40 minutes treatment.
As shown in figure 3.32A, no change in cell morphology was seen. On assaying
the effect of AEA on cell viability, no significant change in cell viability was
observed (Figure 3.32B).
3.13 Anandamide has no effect on membrane integrity in ventricular
myocytes
Membrane integrity was assessed using the lactate dehydrogenase (LDH)
assay. LDH is a soluble enzyme located in the cytosol which is released into the
surrounding culture medium upon cell damage or lysis, a process that commonly
correlates with both apoptosis and necrosis (Bonfoco, et al., 1995). The levels of
LDH released into the surrounding media can, therefore, serve as a reliable
measurement for cytotoxicity. Cell death was induced by 1 % Triton X-100
(Abood, et al., 2001) and was set to be total LDH activity (100 %). Data from
control and treated cells were normalized to total LDH release and calculated as
percentage cytotoxicity. Results of the LDH assay are summarized in Figure 3.33.
As depicted in the figure, no significance difference in LDH activity was observed
between vehicle and AEA-treated cells.
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Figure 3.32 Effect of AEA on morphological characteristics and cell viability
of ventricular cardiomyocytes: (A) Ventricular cardiomyocytes were treated
with either vehicle or 10 µM AEA for 40 minutes. (B) Effect of vehicle, AEA, or
metAEA on cell viability as determined by MTT assay. Data are analyzed using
ANOVA and are expressed as means ± S.E.M. of five independent experiments. *
indicates statistically different from the control values at the level of P<0.05.
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Figure 3.33 Cytotoxicity of AEA as assessed by LDH assay: Cells are treated
with vehicle or vehicle + AEA (10 μM) for 40 minutes. Values represent means ±
S.E.M., expressed as a percentage of the total LDH activity induced by 1 % Triton
X-100. Data are analyzed using independent sample t-test and are expressed as
means ± S.E.M.
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4. DISCUSSION
The results of this study indicate for the first time that impaired Ca2+
signaling underlies the negative inotropic actions of AEA in rat ventricular
myocytes, and that direct interaction of AEA with ion channel(s) shaping APs,
rather than the activation of known cannabinoid receptors, mediate, at least in
part, the effects of AEA on myocyte contractility. These findings also show that
AEA-induced alterations in APs of myocytes are due to direct inhibition of
voltage-dependent Na+ and Ca2+ channels. In addition, the results of this study
indicate for the first time that under normal conditions, AEA can directly inhibit
the activity of NCX1 in ventricular myocytes.
Systemic administration of AEA causes complex hemodynamic changes
involving phases of both increased and decreased blood pressure as well as
changes in heart rate and contractility (for reviews, Randall, et al., 2004; Batkai
and Pacher, 2009). It has been suggested that these cardiovascular actions of
endocannabinoids involve multiple sets of cellular and molecular mechanisms
(Randall, et al., 2004; Malinowska, et al., 2012). In addition to receptor-mediated
and direct actions of endocannabinoids on muscular structures, neuronal and
endothelial cells have also been shown to be influenced by AEA and its metabolic
products (Oz, 2006).
The use of video edge detection in individual myocytes has several
advantages over in vivo experiments and traditional in vitro systems such as
Langendorff-perfused heart preparation, since it allows measurement of
contractility at single-cell level in a relatively isolated environment and excludes
the influence of autonomic nerve endings, gap-junctions, neurotransmitter uptake
system, and coronary perfusion status (Oz et al., 2006; Malinowska, et al., 2012).
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For example, AEA has been reported to inhibit noradrenaline release from atrium
subjected to electrical field stimulation (Goodfellow and Glass, 2009) and to
enhance vagal activity (for a review, Malinowska, et al., 2012) in in vivo and in in
vitro muscle preparations. Similarly, the modulation of the functional properties of
dopamine (DA), serotonin, and glycine transporters and gap junctions (Venance,
et al., 1995) by AEA and AA has been reported in neurons, cultured neurons, glia,
and synaptosomal preparations (Chen, et al., 2003; Pearlman, et al., 2003; Steffens
and Feuerstein, 2004; Oz, et al., 2010). However, it is unlikely that these reuptake
mechanisms are involved in our studies on ventricular myocytes. Therefore, using
acutely isolated ventricular myocytes, we have been able to bypass various
potential target sites for AEA, and focus on characterizing its action on
cardiomyocytes.
4.1 Myocyte shortening and intracellular Ca 2+ measurements experiments
In myocyte shortening experiments, bath application of AEA caused a
significant reduction in the maximal shortening amplitudes without causing
significant alteration in the time course of myocyte contraction. Negativeinotropic actions of AEA might be attributed to the impaired release of Ca 2+ from
the SR. In fact, AEA and other various cannabinoid receptor agonists have been
reported to modulate the ryanodine sensitive intracellular Ca2+ stores and Ca2+ATPase activity in various cell types (Epps, et al., 1982; Mombouli, et al., 1999;
Zhuang, et al., 2005; Rao and Kaminski, 2006); for recent reviews, (Goodfellow
and Glass, 2009; De and Di, V, 2009b). However, in our recent study (Al Kury, et
al., 2014a), we have shown that binding of ryanodine to SR membranes was not
altered by AEA. Similarly, in the presence of AEA (0.1 and 1 µM), passive Ca2+
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release from SR membrane vesicles remained unchanged. In line with these
findings, in the current study, the amplitude and kinetics of caffeine-induced Ca2+
release from intracellular Ca2+ stores were not altered by AEA. Collectively, these
results indicate that ryanodine-sensitive intracellular Ca2+ stores are not involved
in the negative inotropic effects of AEA.
On the other hand, the decrease in THALF decay and AMP of the Ca2+
transient by AEA during twitch responses may be due to increased uptake of
cytosolic Ca2+ to SR. In fact, our recent study (Al Kury, et al., 2014a), indicates
that AEA, (0.1 and 1 µM) caused a significant increase in Ca2+-ATPase activity in
cardiac SR membranes suggesting that increased Ca2+ uptake by SR might
contribute to the observed changes in Ca2+ transients. Interestingly, NAEs with
varying carbon chain lengths (Epps, et al., 1982) and fatty acid-based compounds,
such as AA, have also been shown to modulate the activity of Ca2+-ATPase in
cardiac and skeletal SR membranes. Potentiation of the Ca2+-ATPase activity
without altering Ca2+ release and ryanodine-binding to the Ca2+ release channel
may account for the decrease in THALF decay and amplitude of the Ca2+ transient
caused by AEA (1 µM). Decreases in THALF decay and amplitudes of the Ca2+
transients by low concentration of AEA (1 µM) during twitches, but not caffeineinduced Ca2+ transients, may suggest that compared to caffeine-induced responses
which involve the release of large amounts of Ca2+ from SR, fast Ca2+ transients
during electrical stimulations are relatively more sensitive to alterations in Ca 2+ATPase activity.
Activation of cannabinoid receptors alters the levels of second messengers
such as cAMP, cGMP and protein kinase C (Demuth and Molleman, 2006;
Goodfellow and Glass, 2009) which are known to be involved in tuning the Ca2+
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sensitivity of the contractile proteins. However, sensitivity of contractile proteins
to intracellular Ca2+ remains unchanged in the presence of AEA, suggesting that
phosphorylation and de-phosphorylation of the contractile proteins do not play a
significant role in the negative inotropic actions of AEA. An earlier study in
isolated rat atria demonstrated that AEA caused negative inotropic effects by
decreasing cAMP and increasing nitric oxide (NO) levels (Sterin-Borda, et al.,
2005). However, AEA still decreased contractile performance in the presence of
L-NAME, a NOS inhibitor, excluding a NO-mediated negative inotropic effect on
human atrial muscle (Bonz, et al., 2003). Similarly, in another study in rat isolated
heart, the negative inotropic actions of synthetic cannabinoid HU-210 were not
correlated with the intracellular concentrations of cAMP and cGMP (Maslov, et
al., 2004). Collectively, these findings, in agreement with the results of the current
work, suggest that the effects of AEA on myocyte contractility are not related to
changes in intracellular Ca2+ release machinery or sensitivity of myofilaments to
Ca2+. Furthermore, in the presence of AEA (1 µM), intracellular Ca2+ levels and
resting cell length of ventricular myocytes remain unaltered suggesting that AEA
does not significantly affect Ca2+ homeostasis under resting conditions.
In several earlier investigations, it has been reported that in the
concentration range used in our study, AEA activates TRP channels such as
TRPV1 receptors and causes increased levels of intracellular Ca2+ in various cell
types (De and Di, V, 2010; Bradshaw, et al., 2013). However, TRP channels are
not likely to be involved in the observed actions of AEA in cardiomyocytes for the
following reasons. First, TRP channels are highly permeable to Ca2+ and their
activation

causes

increased

intracellular

Ca2+

concentrations.

However,

application of AEA (0.1 to 1 µM) does not cause any alteration in intracellular
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Ca2+ levels. Secondly, any opening of TRP channels would be associated with
decreased input resistance of the cell, and we have not observed a detectable
change in the input resistance of myocytes during voltage clamp experiments.
Thirdly, in earlier studies, TRPV1 channels, the main TRP channel subtype that is
activated by AEA, are not expressed in adult cardiomyocytes (Dvorakova and
Kummer, 2001).
AEA is metabolized by FAAH and degradation products such as AA, and
AA derivatives have been shown to cause negative inotropic actions in
cardiomyocytes (Hoffmann, et al., 1995; Mamas and Terrar, 2001; Liu, 2007).
However, metAEA, the non-hydrolyzed analogue of AEA (Abadji, et al., 1994),
also decreases the shortening of myocytes. In addition, AEA continues to inhibit
myocyte shortening after pretreatment of these cells with URB597, a specific
inhibitor of FAAH (Piomelli, et al., 2006). Furthermore, the negative inotropic
effects of AEA are also insensitive to indomethacin application, indicating that the
effect was unlikely to involve the stimulation of the release and metabolism of
endogenous AA. These findings provide evidence that degradation products of
AEA are not involved in the observed effects of this compound. Collectively,
myocyte shortening experiments indicate that the negative inotropic effect of AEA
results from a direct interaction of AEA with ventricular myocytes, rather than its
action on nerve endings and neurotransmitter uptake systems that have been
reported in various neuronal structures (Ishac, et al., 1996; Oz, et al., 2010).
4.2 Involvement of cannabinoid receptors in the negative inotropic effect
Involvement of cannabinoid receptors in the negative inotropic actions of
cannabinoids has been reported in several earlier studies (Ford, et al., 2002; Bonz,
et al., 2003; Sterin-Borda, et al., 2005; Su, et al., 2011). However, the results of
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these investigations have not been conclusive (for reviews, Malinowska, et al.,
2012; Randall, et al., 2004; Mendizabal and Adler-Graschinsky, 2007). Both
cannabinoid receptor-dependent and -independent mechanisms have been
suggested (Malinowska, et al., 2012). While Ford et al., showed that in rat cardiac
muscle, the inhibitory effect of AEA on contractility was not reversed in the
presence of CB1 (SR141716A) and CB2 (SR144528) receptor antagonists (Ford, et
al., 2002), Bonz et al. reported that AEA, metAEA, and HU-210 decreased
contractile performance in human atrial muscle via activation of CB1 receptors
(Bonz, et al., 2003). In another study in rat atria, AEA was suggested to have
negative and positive inotropic effects mediated by the activation of CB1 and CB2
receptors, respectively (Sterin-Borda, et al., 2005). Under our experimental
conditions, two structurally different CB1 antagonists AM251 (0.3 μM) and
SR141716 (0.3 μM) are not able to reverse the inhibitory effect of AEA on
cardiomyocyte shortening. Similarly, two different CB2 antagonists AM630 (0.3
μM) and SR144528 (0.3 μM) fail to antagonize AEA-induced decrease of
cardiomyocyte shortening. However, at higher concentrations such as 1 μM, these
antagonists themselves show inhibitory actions on cardiomyocyte shortening
(n=9-12). To our knowledge, the negative inotropic actions of relatively high
concentrations of AM251 and AM630 have not been reported previously.
However, negative inotropic actions of SR141716 and SR144528 on the
contractile functions of isolated rat heart have also been attributed to their direct
effects on the contractility of cardiomyocytes (Krylatov, et al., 2005). Earlier
studies on cardiac muscle and other preparations also indicate that cannabinoid
receptor antagonists with different chemical structures can have off-target binding
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sites on various ion channels and enzymes (Ford, et al., 2002; Batkai, et al.,
2004a; Patil, et al., 2011; Baur, et al., 2012).
4.3 Action potential measurements
During excitation-contraction coupling, alterations in the amplitudes and
kinetics of cardiac APs are closely associated with corresponding changes in the
contractility of myocytes. In agreement with several earlier electrophysiological
studies on rat ventricular myocytes, we have identified two distinctly different
groups of cells displaying either epicardial (short duration) or endocardial (long
duration) APs (for a review, Antzelevitch, et al., 1991). In the current study, low
AEA concentration (0.1 µM) does not cause significant alterations in amplitudes
and kinetics of APs in either epicardial or endocardial myocytes (Figure 3.11).
However, there is a slight hyperpolarization in Vrest values, which reaches a
statistically significant level at 1 µM AEA. At this concentration, AEA decreases
the durations of APs without significantly affecting the amplitudes and dV/dtmax of
APs. At higher concentration (10 µM), AEA induces changes in AP duration
accompanied with depolarization of the Vrest and decreases of dV/dtmax in the
endocardial and epicardial ventricular myocytes, suggesting that AEA acts on
multiple ion channels with different potencies. Importantly, no change in APD60
was observed in a subpopulation of cells, suggesting that some of the actions of
AEA on these channels are cell specific.
Although, this is the first patch clamp study investigating the effect of
AEA on the cardiac APs, an earlier report using intracellular recording methods in
rat papillary muscle fibers reported that AEA, in the concentration range of 1-100
nM, potently inhibited AP durations in an AM251 sensitive manner (Li, et al.,
2009), suggesting that activation of CB1 receptors mediated the negative inotropic
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actions of AEA. However, under the experimental conditions of this study,
changes on neither amplitudes nor kinetics of epicardial and endocardial APs are
detectable until 1 μM concentration of AEA. Importantly, the effects of AEA on
the duration of both types of APs are not reversed in the presence of CB receptor
antagonists tested; AM251 and AM630 (Figure 3.13A and B). In addition, AEA
continues to affect AP duration after PTX pretreatment (Figure 3.14C). It is likely
that differences in methods (patch clamp versus intracellular sharp electrode
recording) and preparations (ventricular myocytes versus intact muscle fibers with
nerve endings and gap junction connections) used in these studies may account for
some of the discrepancies.
In summary, based on the insensitivity of the effect of AEA on myocyte
shortening and action potential shortening to CB1 and CB2 antagonists, as well as
to the pretreatments with PTX and NEM, it is likely that AEA decreases myocyte
shortening and shortens AP duration in a manner that is independent of CB1 and
CB2 cannabinoid receptors.
4.4 Experiments with voltage-dependent Na+ channels
In cardiac muscle, extracellular Ca2+ required to trigger Ca2+ release from
SR enters through L-type VGCCs which are opened during the AP. The results
using voltage-clamp mode of whole-cell patch clamp technique indicate that in
agreement with the changes in the amplitudes, duration and dV/dtmax of APs, AEA
caused significant inhibition of voltage-dependent Na+ and L-type Ca2+ channels
in cardiomyocytes. Furthermore, the results indicate that the inhibition of these
channels by AEA is not sensitive to CB1 or CB2 receptor antagonists. These
findings are in agreement with the direct inhibition of Na+ and L-type Ca2+
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channels observed in earlier studies. For example, AEA, at similar or higher
concentrations, has been shown to inhibit directly the functions of voltage-gated
Na+ channels in neuronal structures (Nicholson, et al., 2003; Kim, et al., 2005;
Duan, et al., 2008), L-type Ca2+ channels (Oz, et al., 2000; Oz, et al., 2004b) and
various types of K+ channels (Oz, et al., 2007a; for a review, Oz, 2006).
In cardiac muscles, VGSCs are almost exclusively represented by their
TTX-resistant Nav1.5 isoform (Catterall, et al., 2005a). Therefore, the changes in
the biophysical properties of INa by AEA, namely induction of the hyperpolarizing
shift in the voltage-dependence of its SSI can be attributed to their effects on the
gating of Nav1.5 channel. A hyperpolarizing shift of the SSI indicates that a
higher proportion of VGSCs would be inactivated at resting membrane potential
and therefore, substantially fewer channels would be available for activation,
resulting in a decreased amplitude and rate of rise during the upstroke of the AP.
Our previous radioligand studies indicated that the specific binding of
[3H]BTX-B to ventricular muscle membranes was inhibited by metAEA. In
addition, the results with CB1 and CB2 antagonists suggested that the effect of
metAEA on VGSCs was not mediated by the activation of CB1 or CB2
cannabinoid receptors (Al Kury, et al, 2014b, article In Press). Earlier
investigations have shown that local anesthetics and class I antiarrhythmics also
interact with the binding site for [3H]BTX-B on the cardiac sodium channel
(Sheldon, et al., 1994). It is likely that AEA synthesized during cell stress can bind
to Nav1.5 channel and modulate the actions of local anesthetics and class I
antiarrhythmics. Although, this to our knowledge, is the first demonstration of the
direct inhibitory action of AEA on a muscle type voltage-dependent Na+ channel,
in several earlier investigations, AEA, at similar or higher concentrations, has
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been shown to inhibit directly the function of VGSCs in neuronal structures
(Nicholson, et al., 2003; Kim, et al., 2005; Duan, et al., 2008). In agreement with
our findings, both AEA (Theile and Cummins, 2011) and its metabolite AA
(Bendahhou, et al., 1997) have been shown to increase the inactivation of Na+
channels. Inhibition of VGSCs by AEA would slow the conduction of
depolarization and modulate the automaticity in the ventricles.
In conclusion, the inhibitory effect of AEA, on VGSC, which is the major
inward current during the upstroke (phase 0) of the AP is in agreement with the
results of the current-clamp experiments (Al Kury, et al., 2014a) indicating that
AEA decreases the amplitude and initial rate of rise of the AP in ventricular
myocytes.
4.5 Experiments with voltage-dependent Ca2+ channels
In addition to INa, AEA causes a significant inhibition of IL,Ca in
cardiomyocytes. This current contributes to the plateau of the cardiac AP (phase
2), therefore, its suppression causes both the decrease of plateau amplitude and the
shortening of the AP duration. The results of this work, in agreement with an
earlier study (Li, et al., 2009), show that AEA decreases the amplitude of the
plateau and causes shortening of AP duration. Results also show that AEA affects
the activation and inactivation gating of cardiac L-type VGCCs producing a
significant reduction in I L,Ca “window current” in the range of Vm between -40
mV and +10 mV, and inducing partial blockade of the ion-conducting pathway
leading to decreased amplitude of I L,Ca.
Diminished stationary Ca2+ entry as a consequence of smaller “window
current” may prevent Ca2+ overload and cause reduction of necrosis, whereas,
inhibition of IL,Ca may largely determine the decrease in the amplitude of AP
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plateau and AP shortening observed in the presence of AEA. Collectively, the
results of the electrophysiological experiments suggest that during excitationcontraction coupling, shortening of AP due to the inhibition of L-type Ca2+
channels decreases Ca2+-induced Ca2+ release from SR and causes negative
inotropic effect of AEA reported in earlier studies. In line with this hypothesis,
although caffeine-induced Ca2+ transients and myofilament sensitivity to Ca2+
remain unchanged, electrically-induced Ca2+ transients are significantly depressed
by AEA, further suggesting that Ca2+-induced Ca2+ release is impaired in the
presence of AEA. Overall, AEA-mediated suppression of voltage-activated IL,Ca
would provide a mechanism for the negative inotropic effects observed in earlier
studies.
The mechanism of the inhibitory effect of AEA does not seem to involve
the Ca2+-induced inactivation process, since the amplitudes of Ba2+ currents
through L-type VGCCs were effectively inhibited by AEA. In addition, AEA was
equally effective upon intracellular or extracellular application suggesting that
there is no sidedness for AEA actions on L-type VGCCs. Considering the highly
lipophilic nature of AEA; it is not surprising that AEA can access its binding site
from both extra and intracellular sites effectively.
The results of our radioligand binding studies also indicated that AEA
directly interacts with and inhibits the function of L-type Ca2+ channels in
ventricular muscle membranes (Al Kury, et al., 2014b, article In Press). Although,
to our knowledge, this is the first demonstration of the direct effects of AEA on
the L-type VGCC in cardiac muscle, similar results demonstrating the effects
AEA on skeletal muscle L-type VGCCs have also been described in biochemical
studies (Oz, et al., 2000; Oz, et al., 2004a). In rabbit skeletal muscle, it has been
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demonstrated that AEA inhibits the specific binding of [ 3H]Isradipine to skeletal
T-tubule membranes, and directly inhibits the function of skeletal muscle L-type
Ca2+ channels (Oz, et al., 2000; Oz, et al., 2004a) in a manner that is independent
of known cannabinoid receptors. In fact, earlier studies searching for endogenous
modulators of L-type Ca2+ channels have also identified AEA as a ligand for Ltype Ca2+ (Johnson, et al., 1993). Subsequently, investigations indicated that the
effects of AEA are not limited to L-type VGCCs in muscles. Different types of
Ca2+ currents in neurons and other excitable cells are also inhibited directly by
endocannabinoids such as AEA [for a recent review, (Lozovaya, et al., 2009)].
In a recent study, it was found that the synthetic cannabinoid A-955840
inhibits the function of L-type Ca2+ channels in rabbit heart in a manner
insensitive to CB1 and CB2 antagonists (Su, et al., 2011). In another recent study,
AEA was reported to inhibit L-type Ca2+ channels by the activation of CB1
receptors (Li, et al., 2009). In this study, AEA in the concentration range of 10 nM
to 1 µM potently inhibited the function of Ca2+ channels and the effect of AEA
was reversed by CB1 receptor antagonists. In our experiments, AEA is not
effective at concentrations lower than 0.1 µM. In addition, in our study, the
inhibitory effect of AEA is not reversed by the antagonists of CB1 and CB2
receptors. The differences between these two studies could be due to different
strains of rats used (Sprague-Dawley in their study versus Wistar rats in the
present study). Our findings suggest that neither CB1 nor CB2 receptors are
involved in AEA inhibition of L-type Ca2+ channels in rat cardiomyocytes.
Although PTX-sensitive signal transduction is well documented for cannabinoid
agonists, cannabinoid coupling to PTX-insensitive Gq has been reported in several
studies (McIntosh, et al., 2007; Straiker, et al., 2002; Ishii and Chun, 2002).
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Therefore, the effect of AEA through a PTX-insensitive pathway cannot be
excluded. However, the results of our experiments with NEM, which inactivate Gproteins indicate that activation of G-proteins is not required for AEA actions in
cardiomyocytes.
Degradation products of AEA, such as AA and fatty acids-based
compounds, have been shown to inhibit the function of cardiac L-type Ca2+
channels [(Li, et al., 2009), for a review; (Oz, 2006)]. However, metAEA also
inhibited L-type Ca2+ currents to the same extent with AEA. In addition, AEA
continued to inhibit L-type Ca2+ currents after pretreatment of these cells with the
specific inhibitor of FAAH, URB597 (Piomelli, et al., 2006).
4.6 Experiments with cardiac Na +/Ca2+ exchanger
The results of this study indicate for the first time that under normal
conditions, AEA has a direct inhibitory effect on both the forward and reverse
mode of NCX1 in ventricular myocytes. Under physiological conditions,
inhibition of NCX1 operating in reverse mode is expected to decrease Ca 2+
entrance during cardiac action potential, and induce negative inotropic actions.
Therefore, it is likely that the inhibition of NCX function in the reverse mode can
cause the suppression of AP plateau and the decrease of the AP duration.
The findings of this study suggest that neither CB1 nor CB2 receptors are
involved in AEA inhibition of NCX in rat cardiomyocytes. Firstly, AEA
inhibition is altered by neither CB1 nor CB2 receptor antagonists. Secondly,
treatment with PTX or inclusion of GDP-β-S in pipette solution does not affect the
activity of NCX1 further suggesting that G-proteins are not involved in AEA
actions. Thirdly, in our recent study (Al Kury et al., 2014c) we have shown that
AEA significantly inhibited NCX1-mediated currents in HEK-293 cells which do
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not contain CB1 or CB2 receptors (Oz, et al., 2010). Collectively these results
suggest that AEA interacts directly with NCX1 in ventricular myocytes in a
manner that is independent of CB1 and CB2 receptors.
In rat odontoblasts, cannabinoid-induced Ca2+ inﬂux through TRPV1 was
recently shown to be functionally coupled to NCX-mediated Ca2+ extrusion
(Tsumura, et al., 2012). However, it is unlikely that TRPV1 activation is involved
in the effects of AEA observed in this study since adult cardiomyocytes do not
express TRPV1 channels (Dvorakova and Kummer, 2001). In another recent
study, it was reported that under ischemic conditions, AEA inhibits NCX1 by
activating CB2 receptors via PTX-sensitive Gi/o proteins (Li, et al., 2013).
However, a recent study in endothelial cells demonstrated that AEA, in the
concentration range used in our study, significantly inhibits the activity of NCX1
in a manner that is independent of G-protein receptors (Bondarenko, et al., 2013).
Metabolic degradation products of AEA, such as AA and related fatty
acids have also been shown to regulate NCX1 function (Xiao, et al., 2004). In the
current study, the metabolically stable analogue of AEA, metAEA (Abadji et al.,
1994), also inhibits INCX1. Furthermore, in the presence of URB597, INCX1 is
suppressed to the same extent by AEA, suggesting that the degradation products
of AEA are not involved in the inhibition of NCX1 in cardiac myocytes. In our
recent study in HEK-293 cells (Al Kury et al., 2014c), cell surface expression of
NCX1, as determined from the intensity of YFP-NCX1 expression levels, was not
altered after AEA application suggesting that AEA is not likely to alter NCX1
trafficking to the cell surface.
In addition to the NCX, SR Ca2+-ATPase (SERCA2a) also plays an
important role in cardiac contraction and rhythmicity (Inesi, et al., 2008; Eisner, et
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al., 2013). Under the experimental conditions of this work, we cannot rule out the
contribution of SERCA2a to the observed actions of AEA on the function of NCX
in cardiomyocytes. In fact, our recent study (Al Kury, et al., 2014a) indicates that
AEA causes a significant increase in SERCA2a activity in cardiac SR membranes.
AEA continued to inhibit the NCX1 currents in HEK-293 cells which, although
express SERCA2 endogenously (Vafiadaki, et al., 2009), is devoid of excitability.
Furthermore, bath application of AEA does not alter intracellular Ca 2+ levels in
these cell lines (Oz, et al., 2010).
4.7 Mechanism of action of AEA
Anandamide belongs to long-chain NAEs which are produced abundantly
in response to tissue necrosis and cellular stress (Hansen, et al., 2000; Berger, et
al., 2004). In fact, accumulation of NAEs was first observed in experimental
myocardial infarction induced by ligation of coronary arteries in canine heart
[(Epps, et al., 1979; Epps, et al., 1982), for a review, (Schmid and Berdyshev,
2002)]. Although the content of NAEs in various mammalian tissues ranges from
about 0.1 to 20 nmol/g (Hansen, et al., 2000), it was demonstrated that NAEs
content increases up to 500 nmol/g (approximately 500 μM) in infarcted areas of
canine heart during ischemia (Epps, et al., 1979). AEA constitutes minor (1-3 %)
portion of total NAE levels (Schmid and Berdyshev, 2002), however, the partition
coefficient of AEA is in the same order with that of AA to biological membranes
(2-9 x104) (Meves, 1994). Thus, the membrane concentration of AEA would reach
much higher levels than those estimated for intracellular concentrations.
It was previously reported that other NAE species, such as Nstearoylethanolamine (SEA) and N-oleoylethanolamine (OEA), are also produced
during ischemia and that they have significant effects on the amplitudes and
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kinetics of APs and accompanying ionic currents. The effects of SEA and OEA
could account for the negative inotropic actions of these compounds on
ventricular myocytes (Voitychuk, et al., 2012). Similar to AEA, other NAEs,
metabolic degradation products of NAEs, and structurally related compounds have
been shown to modulate the function of voltage-gated Ca2+ (Voitychuk, et al.,
2012; Oz, et al., 2000; Oz, et al., 2005; Alptekin, et al., 2010) and Na+ (Nicholson,
et al., 2003; Kim, et al., 2005; Duan, et al., 2008) channels. Furthermore, AEA has
been shown to block T-type Ca2+ channels (Cav3.1 and Cav 3.2) (Chemin, et al.,
2007) and cardiac Kv1.5 (Barana, et al., 2010) and Kv4.3 (Amoros, et al., 2010)
channels in a receptor-independent manner. These effects may contribute to the
overall actions of AEA on action potential and cardiac myocyte function.
Therefore, in the concentrations used in this study, AEA is likely to have
important implications regarding the contractile and electrical responses of
ventricular myocytes to ischemia and cellular stress (Hansen, et al., 2000; Berger,
et al., 2004; Schmid and Berdyshev, 2002). In fact, shortening of AP duration by
AEA can be beneficial or harmful, depending on the underlying pathology. Thus,
during acute ischemia, in which the duration of the cardiac AP is already
shortened, a further decrease should be proarrhythmic (Den Ruijter, et al., 2007).
However, shortening of AP duration should be beneficial in preventing those
arrhythmias caused by triggered activities observed in conditions such as heart
failure (Den Ruijter, et al., 2007; Den Ruijter and Coronel, 2009).
Binding site(s) of AEA and other endocannabinoids on their target proteins
is currently unknown. Apart from specific binding sites on the ion channels and
receptors (Figure 4.1), AEA can accumulate and reach substantially high
concentrations in biological membranes, thereby causing significant alterations in
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physico-chemical properties of these membranes. As mentioned earlier, the
membrane concentration of AEA can reach much higher levels than those
estimated for intracellular or extracellular concentrations. It is likely that due to its
high lipophilicity, AEA can alter the physico-chemical characteristics of the lipid
environment, or indeed, bind to hydrophobic sites on the ion channels and regulate
the functional properties of these proteins [(Mavromoustakos, et al., 2001); for a
review, (Oz, 2006)]. Concentrations of AEA modulating the activities of ion
channels and exchangers studied in our investigation appear to be within the range
of 0.1 to 10 µM. It is not known whether these concentrations can be achieved
under physiological conditions. The concentrations of AEA in the rat brain have
been reported to range from 2.5 to 29 pmol/g (Schmid, et al., 2002). The
concentration of AEA in rat and human plasma is in the nM range of 0.7–8 nM
and 4-20 nM, respectively (Giuffrida, et al., 2000; Bojesen and Bojesen, 1994).
However, as mentioned earlier, due to high partition coefficients, AEA can
effectively accumulate in cell membranes and reach significantly higher
concentrations. Furthermore, during ischemia and cell stress, tissue concentrations
of AEA can increase further (Epps, et al., 1979; Schmid and Berdyshev, 2002)

154

Figure 4.1 Proposed model for the actions of AEA on cellular excitability:
According to the model, the effects of AEA are mediated by G-protein coupled
cannabinoid receptors, ligand-gated ion channels and voltage-gated ion channels.
CB-R, cannabinoid receptor; LGIC, ligand-gated ion channel; VGIC, voltagegated ion channel. Adapted from Oz, 2006.
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It has been more than a century since the Overton-Meyer rule stated that
membrane permeability of any molecule depends on its hydrophobicity. Although
the Overton-Meyer rule predicts the accessibility of hydrophobic molecules such
as various lipids, fatty acids and endocannabinoids to their membrane-delimited
actions and hence somewhat the potency of these molecules on their target
proteins, it does not elucidate the mechanism(s) of action of these molecules. One
school of thought focuses on the influence of lateral pressure profiles on integral
membrane proteins to describe how proteins sense the effects of hydrophobic
molecules in membrane bilayers (van den Brink-van der Laan, et al., 2004), and
hydrophobic mismatch between the lengths of the hydrophobic membranespanning domains and the bilayer thickness (Lundbaek, 2006). Changes in the
lateral pressure profile with altered lipid composition (Cantor, 2001; Van den
Brink-van der Laan, et al., 2004) or by partitioning of hydrophobic molecules
(Cantor, 2001) have been shown to modulate the functions of ion channels and
other integral membrane proteins. It has been hypothesized that if the hydrophobic
length of the transmembrane domains of the ion channels does not match the
hydrophobic thickness of the membrane phospholipid bilayer, such a mismatch
would create stress between the channel and the membrane (Andersen, et al.,
1999). As a result, this tension requires that the thickness of the cell membrane be
decreased at its contact with the interface of the transmembrane regions of the ion
channel so that their hydrophobic regions match, and thus, affect the
conformational state and conductance of the ion channel (Jensen and Mouritsen,
2004).
In an earlier study, it was suggested that alterations in the lipid order of
synaptic membranes caused by various cannabinoids might be a necessary
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property for their pharmacological activities (Bloom, et al., 1997). However, the
influences of lateral membrane pressure and membrane thickness are not observed
universally, and other membrane properties can also play roles in lipid-protein
interactions (Lee, et al., 2005). Another school of thought on the question of how
lipophilic molecules such as cannabinoids affect the function of ion channels
focuses on the protein-lipid interface. Recent investigations suggest that lipids
such as fatty acids displace or interact with lipids and/or hydrophobic amino acids
located at the specific lipid-protein interfaces of the ion channels, rather than
altering bulk physico-chemical properties of cell membranes (McIntosh and
Simon, 2006). Thus, although hydrophobicity is an important factor determining
the bioavailibilty of the drug at its action site, highly hydrophobic molecules such
as cannabinoids may not need to change bulk membrane characteristics to alter the
function of ion channels (Barrantes, 2004; Garcia, 2004).
An extensive volume of work in the literature indicates that the bilayer is
not simply an inert thin layer of lipid whose primary purpose is to provide a
barrier to ions (McIntosh and Simon, 2006). Following their insertion into the
fluid membrane bilayer, ion channels assume an energetically minimal
conformational state leading to a stable structure. Importantly, the binding of
ligands, such as AEA, leads to conformational changes associated with the
alterations in the hydrophobic domains of the ion channels (Lee and MacKinnon,
2004; Lee, et al., 2005; Garcia, 2004). The energetic requirements of these
conformational changes depend on the lipid environment in which they are
immersed (Spivak, et al., 2007). Although the exact mechanisms of action of AEA
on ion channels and receptors are currently unknown, such interaction with
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proteins is likely to mediate some of the pharmacological actions of AEA in the
cardiovascular and nervous systems.
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5. CONCLUSION
In conclusion, the results generated from the present study, indicate for the
first time that AEA inhibits myocyte contractility by acting on multiple target
proteins. We have shown that AEA decreases the duration of APs and modulates
the activity of Na+ and L-type Ca2+ channels and inhibits the function of NCX1 in
a CB1 and CB2 receptor-independent manner. Considering massive release of
various NAEs, including AEA, during ischemia and hypoxic conditions, further
understanding of their action mechanisms and target proteins is essential in the
development of better treatment modalities for these pathological conditions.
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6. LIMITATIONS AND FUTURE WORK


The main work limitations in this study are:

1. Physiological temperature: All patch clamp experiments were conducted at
room temperature (22-23 °C) in order to ensure longer survival time of patched
cells and a better time resolution of the membrane currents. Giga-ohm seals in
patch-clamp experiments are known to be unstable at raised temperatures. For this
reason, we chose to work at room temperature. A similar approach was taken in
earlier studies in various cell types (Voitychuk et al., 2012; Li et al., 2013;
Bondarenko et al., 2013).
2. The influence of solvent: AEA was dissolved in ethanol. As with earlier studies,
ethanol alone caused a decrease in the contractility of ventricular myocytes and
the amplitudes of INa and IL,Ca. Therefore, for each set of experiments, it was
necessary to test the effect of the solvent separately.


In order to extend our findings in this thesis, the following experiments
can be done in the future:

1. Our study showed that AEA can decrease the AP amplitude and shorten AP
duration in rat ventricular myocytes which might be one of the mechanisms for
anti-arrhythmic effect of AEA. However, the mechanism of action of AEA is not
completely understood and the effect of AEA on the cardiac conduction system
remains unknown. Therefore, investigating the effect of AEA on sinoatrial and
atrioventricular nodes would be very informative.
2. In addition to the endocannabinoid AEA, levels of 2-AG have been shown to be
increased in a range of cardiovascular disorders. Therefore, understanding the
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electrophysiological and pharmacological effects of this endogenous cannabinoid
in the heart may aid in further understanding of any potential role of 2-AG in
cardiovascular pathologies.
3. Cardiac K+ channels play an important role in determining the resting
membrane potential and the shape and duration of the cardiac AP. Although the
effect of AEA on outward K+ currents (Ito) and ATP-sensitive K+ currents (IATP)
has been shown previously, the contribution of other K+ conductances such as the
rapid (IKr) and slow (IKs) components of the delayed rectifier and the inward
rectifier (IKI) remains unknown. Therefore, studying the effect AEA on these
conductances would help in better understanding the mechanism of action of AEA
on cardiac cells.
4. Since the kinetics and voltage dependence of channel gating are modified by
auxiliary subunits of voltage gated Na+ and Ca2+ channels, studying the direct
effect of AEA on different subunits of voltage-gated ion channels, using
expression systems such as Chinese Hamster Ovary (CHO) or Human Embryonic
Kidney (HEK) 293 cells, would give a more detailed picture on the mechanism of
the direct effect of AEA on these channels.
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